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ABBREVIATIONS 
ER  : Estrogen Receptor 
PR  : Progesterone Receptor 
HER 2 NEU : Human epidermal growth factor receptor 2 
CK 5/6 : Cytokeratin 5/6 
EGFR  : Epidermal growth factor receptor 1 
DNA  : De oxy ribonucleic acid 
BMI1  : B cell specific Moloney murine leukemia virus insertion  
   site gene 
IHC  : Immunohistochemistry 
PCR  : Polymerase chain reaction 
RT PCR : Reverse Transcriptase Polymerase Chain Reaction 
IDC NOS : Invasive ductal carcinoma not otherwise specified 
ICMR  :  Indian Council of Medical Research 
WHO  : World Health Organisation 
FISH  : Fluorescent in situ hybridization 
cDNA  : complementary deoxy ribonucleic acid 
mRNA : Messenger ribonucleic acid 
GADPH : Glyceraldehyde 3 phosphate dehydrogenase 
ACTB1 : Actin beta 1  
ASCO CAP : American Society of clinical oncologists College of  
  American Pathologists 
CT  : Threshold cycle  
ΔΔCT  : Delta delta threshold cycle 
N  : Number of cases 
SD  : Standard deviation 
SS  : Statistically significant 
NSA  : No significant association 
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 ANNEXURES  
 
ANNEXURE – I 
 
PROFORMA 
 
Case number  :     Name  : 
HPE number  :     Age  : 
IP number  :     Sex  : 
Clinical diagnosis :     Menstrual status : 
Risk factors if any : 
Side of breast : Right/Left 
Specimen  :  Simple Mastectomy / Modified radical mastectomy /  
Radical Mastectomy / Toilet  mastectomy / Others 
GROSS 
Specimen size : 
Nipple areola :      Skin : 
Tumor size  :     Tumor margin: 
Appearance  : 
Resected margins : Superior :  Inferior :  
    Medial :  Lateral  : 
    Posterior : 
Associated findings : 
Total number of nodes dissected :    
Largest node size : 
MICROSCOPY 
Histological subtype: 
Histological score:   Nuclear score:  Mitotic score: 
Modified Scarf Bloom Richardson Grade : I / II /        III 
 
Skin   : Free / Involved 
Nipple & Areola : Free / Involved 
Margins  : Superior :  Free / Involved 
    Inferior   :  Free / Involved 
    Medial    :  Free / Involved 
    Lateral    :  Free / Involved 
    Posterior :  Free / Involved 
Lymphatic invasion: Present / Absent 
Vascular invasion : Present / Absent 
Lymphocytic infiltration:  Present / Absent 
Necrosis  : Present / Absent 
Associated breast lesions : 
Total number of nodes dissected :   
Number of nodes involved: 
ESTROGEN RECEPTOR STATUS 
Proportion score : 
Intensity score : 
Total score  : 
PROGESTERONE RECEPTOR STATUS 
Proportion score : 
Intensity score : 
Total score  : 
HER 2 NEU SCORE : 
Relative expression of Bmi 1 in relation to ACTB1 gene : 
FOLLOW UP 
Chemotherapy :     
Radiotherapy :   
Hormonal therapy : 
Follow up period :      
Present status : 
ANNEXURE II 
WHO HISTOLOGICAL CLASSIFICATION OF EPITHELIAL BREAST TUMORS 
 
INVASIVE BREAST CANCERS   NON INVASIVE BREAST  
       CANCERS 
Invasive ductal carcinoma not otherwise specified Ductal carcinoma in situ 
Mixed type carcinoma    Lobular carcinoma in situ 
Pleomorphic carcinoma    Atypical papilloma 
Carcinoma with osteoclastic type of giant cells  
Carcinoma with choriocarcinomatous features BENIGN EPITHELIAL TUMORS 
Carcinoma with melanotic features     
Invasive lobular carcinoma    Tubular adenoma 
Tubular carcinoma     Lactating adenoma 
Invasive cribriform carcinoma    Apocrine adenoma 
Medullary carcinoma     Pleomorphic adenoma 
Mucinous carcinoma     Ductal adenoma 
Cystadenocarcinoma     Papilloma 
Signet ring carcinoma       
Neuroendocrine tumors     FIBROEPITHELIAL TUMORS 
Solid neuroendocrine carcinoma   Fibroadenoma 
Atypical carcinoid tumor    Phyllodes tumor  
Small cell/oat cell carcinoma    Benign  
Large cell neuroendocrine carcinoma   Borderline   
Invasive papillary carcinoma     Malignant 
Invasive micropapillary carcinoma   Periductal stromal sarcoma  
Metaplastic carcinoma     Apocrine carcinoma 
Pure epithelial metaplastic carcinoma  Mammary hamartoma 
Squamous cell carcinoma     
Adenocarcinoma with spindle cell metaplasia INTRADUCTAL PROLIFERATIVE  
     Adenosquamous carcinoma   LESIONS 
     Mucoepidermoid carcinoma 
Mixed metaplastic carcinoma   Atypical ductal hyperplasia 
Lipid rich carcinoma     Flat epithelial atypia 
Secretory carcinoma     Usual epithelial hyperplasia 
Oncocytic carcinoma 
Adenoid cystic carcinoma    METASTATIC TUMORS 
Acinic cell carcinoma       
Glycogen rich carcinoma 
Sebaceous carcinoma 
Inflammatory carcinoma 
Intraductal papillary carcinoma 
Intracystic papillary carcinoma 
Microinvasive carcinoma 
ANNEXURE III 
NOTTINGHAM MODIFICATION OF SCARF BLOOM 
RICHARDSON GRADING SYSTEM 
 
TUBULE FORMATION SCORE 
Tubule formation in >75% of the tumor 1 
Tubule formation in 10 to 75% of the tumor 2 
Tubule formation in <10 % of the tumor 3 
NUCLEAR PLEOMORPHISM SCORE 
Minimal variation in size and shape of nuclei 1 
Moderate variation in size and shape of nuclei 2 
Marked variation in size and shape of the nuclei 3 
MITOTIC RATE SCORE 
<10 Mitosis per 10 high power field 1 
10 to 20 mitosis per 10 high power field 2 
>20 mitosis per 10 high power field 3 
 
GRADE SCORE 
Grade 1 3,4,5 
Grade 2 6,7 
Grade 3 8,9 
 
 
 
 
 
ANNEXURE IV 
IMMUNOHISTOCHEMISTRY PROCEDURE 
1. 4µ thick sections were cut from formalin fixed paraffin embedded tissue 
samples and transferred to gelatin-chrome alum coated slides. 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2 
changes. 
5. The sections were washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
7. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 to 25 minutes. 
8. The slides were then cooled to room temperature and washed in running 
tap water for 5 minutes. 
9. The slides were then rinsed in distilled water for 5 minutes. 
10. Wash with appropriate wash buffer (phosphate buffer) for 5 minutes x 2 
changes. 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides in phosphate buffer for 5 minutes x 2 changes.  
13. Cover the sections with power block for 15 minutes. 
14. The sections were drained (without washing) and appropriate primary 
antibody was applied over the sections and incubated for 45 minutes. 
15. The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
16. The slides were covered with SuperEnhancer for 30 minutes. 
17. The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
18. The slides were covered with SS Label for 30 minutes. 
19. Wash in phosphate buffer for 5 minutes x 2 changes. 
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1 
ml of DAB buffer. 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. Wash with phosphate buffer solution for 5 minutes x 2 changes. 
23. The slides are washed well in running tap water for 5 minutes. 
24.  The sections were counterstained with Hematoxylin stain for 2 seconds (1 
dip). 
25. The slides are washed in running tap water for 3 minutes. 
26. The slides are air dried, cleared with xylene and mounted with DPX.  
    
ANNEXURE V 
QUICK SCORING SYSTEM FOR ESTROGEN AND 
PROGESTERONE RECEPTOR EXPRESSION 
SCORE FOR PROPORTION 
 
Proportion of nuclei stained Score 
No nuclear staining 0 
<1% nuclear staining 1 
1 – 10% nuclear staining 2 
11 – 33%  nuclear staining 3 
34 – 66%  nuclear staining 4 
67 – 100%  nuclear staining 5 
 
SCORE FOR INTENSITY 
Intensity of nuclear staining Score 
No staining 0 
Weak staining 1 
Moderate staining 2 
Strong staining 3 
 
The score for proportion and the score for intensity are summated to a 
maximum total score of 8. Score of more than 2 is considered as positive. 
ANNEXURE VI 
HER 2 NEU SCORING SYSTEM – ASCO CAP GUIDELINES 
Staining pattern Score Her2neu expression 
No staining in tumor cells 0 Negative 
Weak, incomplete membrane staining in 
any proportion of tumor cells 
1+ Negative 
Weak, complete membrane staining in less 
than 10% of tumor cells 
1+ Negative 
Weak, complete membrane staining in 
more than 10% of the tumor cells 
2+ Borderline 
Complete intense membrane staining in 
less or equal to 30% of tumor cells 
2+ Borderline 
Uniform intense, complete membranous 
staining in more than 30% of tumor cells 
3+ Positive  
 
ANNEXURE VII 
RNA EXTRACTION 
1. 10 Sections of formalin fixed paraffin embedded tissue samples with 
10 µ thickness were collected in micro centrifuge tube. 
2. Sections were cleared with 1 ml xylene, vortex, centrifuged for 2 
minutes and supernatant was removed. 
3. Sections were dehydrated with absolute ethyl alcohol, vortex, 
centrifuged for 2 minutes and supernatant was removed. 
4. The air dried tissue pellet was resuspended in 240 µl Buffer PKD & 
10µl proteinase K mixture to reverse the formaldehyde modification of 
nucleic acid. 
5. Incubate the centrifuge tube at 55ºC for 15 minutes and 80ºC for 15 
minutes. 
6. 500µ of Buffer RBC was added to the mixture and vortex to adjust the 
binding condition. 
7. All the centrifuge tube contents were transferred to gDNA eliminator 
spin column placed in 2 ml collection tube. 
8. The tube is centrifuged at 13,000 rpm for 30 sec to filter the genomic 
DNA in the tissue sample. 
9. The column with genomic DNA was discarded and the flow through 
was saved. 
10. 1200ml of 100% ethanol was added to the flow through and mixed 
well to enable precipitation of RNA in sample. 
11. RNA precipitates were then filtered in RNeasy Minelute spin column 
placed in 2 ml collection tube by centrifuging at 13,000 rpm for 15 
seconds. 
12. The column with RNA precipitate was transferred to another collection 
tube and 500 µl of Buffer RPE  added and centrifuged at 13,000 rpm 
for 15 seconds and then the flow through was discarded. 
13. Step 12 is repeated for 2 minutes. 
14. Transfer RN easy Minelute spin column to a new 2 ml collection tube 
and centrifuged at 13,000 rpm for 5 minutes with their lids open to 
remove the residual ethanol form RNA and the flow through was 
discarded. 
15. Transfer RNeasy Minelute spin column to a new 1.5 ml collection tube 
and 30 µl of RNAse free water was added and centrifuged for 1 minute 
at 13,000 rpm to elute total RNA. 
16. The total RNA was stored at -20ºC to -70ºC. 
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KEY TO MASTERCHART 
 
SI  - Skin infiltration  
LI  - Lymphatic invasion 
VI  - Vascular invasion 
LCI  - Lymphocytic infiltration 
NEC  - necrosis 
LNS  - Lymph node status 
ER  - Estrogen receptor total Quick score 
PR  - Progesterone receptor total Quick score 
HER2 - Human epidermal growth factor receptor score 
CK5/6 - Cytokeratin 5/6 
BMI 1   - Relative concentration of Bmi 1 mRNA in relation to 
actin B-1 gene 
MRM  - Modified radical mastectomy 
SM  - Simple mastectomy 
RM  - Radical mastectomy 
TM  - Toilet mastectomy 
PSM  - Palliative simple mastectomy 
A  - Absent 
P  - Present / positive 
M  - Male 
F  - Female 
R  - Right 
L  - Left 
NAC  - Neoadjuvant chemotherapy 
IDC NOS  - Invasive ductal carcinoma not otherwise specified 
Sup  - superior 
Inf  - inferior 
Med  - medial 
Lat  - lateral 
Post  - posterior 
G  - Grade 
ACC  - Adenoid cystic carcinoma 
MPC  - Micropapillary carcinoma 
N  - Negative 
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INTRODUCTION 
Carcinoma of breast is one of the most common human neoplasms 
both in developed and developing countries accounting for 23% of all the 
cancers in females.1 There is a steady rise in the incidence of breast cancer 
worldwide. It is the leading cancer among Asian women. Early detection and 
advances in treatment have begun to reduce mortality rates.   
Breast carcinoma exhibits a wide range of morphological phenotypes. 
The histological appearances of tumor cannot fully reveal the prognosis. 
Exploration of the molecular pathways of carcinogenesis provides explanation 
for the different morphologic phenotypes and behavior. A large number of 
genetic alterations have been identified in breast carcinoma, many of which 
have potential prognostic and predictive values. Thus estrogen and 
progesterone receptor expression predict response to tamoxifen therapy and 
Her2neu over expression predict response to trastuzumab. 
 Recent research in breast biology has provided support for the cancer 
stem cell hypothesis. Tumor originates from the tissue stem cells through 
dysregulation of the normally tightly regulated process of self renewal.2 
Cancer stem cells have the potential to self renew and differentiate to generate 
phenotypically derived cancer cells.3The polycomb gene Bmi1 is the critical 
regulator of self renewal of stem cells and is over expressed in breast cancer.4 
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 Genomic studies provide a new method of classification of breast 
cancers based on gene expression patterns5,6,7,8,9. Recently 
immunohistochemical markers such as ER, PR, Her 2 neu, CK5/6 and EGFR 
have been used as surrogates for DNA microarray in subtyping breast 
cancer10. These subtypes predict outcome, patient response to chemotherapy 
or targeted therapy.7, 8, 11 
 Thorough use of molecular techniques like immunohistochemistry and 
polymerase chain reaction to study the protein and DNA expression profiles 
may help to predict clinical outcome in individual patients and thus guides to 
plan personalized therapy. 
 In this study of 60 cases, an attempt is made to assess molecular 
subtypes of breast cancers and to compare the Bmi 1 gene and Her 2 neu 
oncoprotein expression with other known prognostic factors. 
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AIMS AND OBJECTIVES 
1. To identify the relative frequency and distribution of breast carcinoma 
in population. 
2. To study the histomorphological features of breast carcinoma including 
grade, lymph node status, lymphovascular invasion, lymphocytic 
response, and necrosis.  
3. To study the immunohistochemical expression of estrogen and 
progesterone receptors in invasive ductal carcinoma breast. 
4. To study the immunohistochemical expression of Her2neu protein in 
invasive ductal carcinoma breast. 
5. To study the Bmi1 gene expression in invasive ductal carcinoma breast 
with respect to grading. 
6. To determine the correlation of   Her2neu and Bmi1 gene expression 
with hormone receptor status and other known prognostic factors such 
as tumor size, histological grade,  axillary node status, presence of 
tumor necrosis, lymphocytic response, lymphatic and vascular invasion 
by tumor. 
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REVIEW OF LITERATURE 
Invasive breast carcinomas are heterogeneous groups of malignant 
epithelial tumors characterized by invasion of adjacent tissues and have a 
marked tendency to metastasize to distant sites.12 
The Edwin Smith Surgical Papyrus (3000-2500 BC) was the first 
document that referred to carcinoma of the breast and concluded that there 
was no treatment for cancer of the breast. In the second century AD, Galen 
gave the classical clinical observation as “the breast tumors exactly resemble 
the animal crab”. Various authors all over the world followed different 
classification of breast cancers.  
In 1925, Greenhough was the first to evaluate grading system for 
breast cancer. In 1928, Scarff EW et al proposed tubule formation, nuclear 
pleomorphism and hyperchromasia as criteria to grade breast cancers. In 
1957, Bloom and Richardson introduced numerical scoring system based on 
tubule formation, nuclear pleomorphism and mitotic rate and that was adopted 
as preferred grading system by WHO.13 In 1983, Bloodgood et al recognized 
ductal carcinoma in situ where neoplastic cells are limited within the terminal 
duct lobular unit. 14 
EPIDEMIOLOGY: 
In 1997, Indian Council of Medical Research (ICMR) documented the 
rise in incidence of breast cancer in India mainly in urban population. It 
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reported that one in 22 women in India has lifetime risk of developing breast 
cancer compared to 1in 8 women in America. Population based survival 
studies revealed five years relative survival for female breast carcinoma 
patients in Chennai was only 45.6%.15 
A study conducted by WHO in 1999 stated that Chennai has the 
highest incidence (26/1,00,000) of breast cancer among all leading cities in 
India.16 Globocan 2008 stated that 1.38 million new cases were diagnosed in 
that year worldwide out of which 8.33% (1,15,000) of the cases were reported 
from India. The reported age standardized incidence rate of breast cancer in 
India is 22.9 per lakh population per year. The mortality rate is relatively high 
accounting for 11.1 per lakh population per year.1 
The presenting symptoms include breast lump, nipple discharge, 
retraction or eczema. Breast abnormalities are evaluated by triple assessment 
including clinical examination, imaging and tissue sampling either by fine 
needle aspiration cytology or core needle biopsy. 
RISK FACTORS: 
The risk factors strongly associated with breast cancers include early 
menarche, late menopause, nulliparity, older age at first child birth, sedentary 
life style with high caloric diet, obesity, use of exogenous estrogens in the 
form of oral contraceptive pills or hormone replacement therapy and positive 
family history of breast cancer in any first degree relative. 12 
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AETIOLOGY: 
The main etiological factors of breast carcinoma include hormone 
excess and genetics. 
The estrogen excess hypothesis states that the increased breast tissue 
proliferation and inhibition of apoptosis occur in the background of 
hyperestrogenism.12 Bernstein et al postulated the higher risk of breast 
carcinoma in women with elevated tissue estrogen and progesterone. 
Classical genetic models of carcinogenesis states that any cell in the breast, 
can be transformed to be malignant by the right combination of mutations.17 
BRCA1gene plays an important role in DNA repair, activation of cell-cycle 
checkpoints, maintenance of chromosome stability and in differentiation of 
stem cells.18 Women with BRCA 1 gene mutation carry 80% lifetime risk of 
developing breast cancer.19 
Recent research in breast biology has provided support for the cancer 
stem-cell hypothesis which was first proposed  more than 150 years ago.20 
Kordon et al. first demonstrated the existence of mammary stem cells in 
mice.21 The cancer stem cell hypothesis states that tumors originate in tissue 
stem and/or progenitor cells through the dysregulation of the normally tightly 
regulated process of self-renewal.2 Cancer stem cells have the potential to self 
renew and some of them undergo differentiation into ductal epithelial cells, 
lobular cells or myoepithelial cells contributing to tumor cellular 
heterogeneity.22 
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 Invasive ductal carcinoma is a group of breast carcinoma in which the 
stromal invasion of malignant cells is evident beyond the epithelial 
component. Current histomorphological sub typing of breast carcinoma is 
based on world health organisation classification. (Annexure II) 
INVASIVE DUCTAL CARCINOMA NOT OTHERWISE SPECIFIED 
(NOS): 
Elston and Ellis et al stated that this is the most common type of 
invasive carcinoma of breast accounting for 75%. WHO defines this as a 
heterogeneous group of tumors that fail to exhibit sufficient characteristics to 
achieve classification as a specific histological type in more than 50% of the 
tumor mass. Grossly, they present as firm to hard grey white mass with 
irregular borders. Microscopy show the tumor cells arranged in cords, 
clusters, trabeculae, syncytial sheets or as tubules with central lumen. These 
tumors are graded using Nottingham modification of Scarf Bloom Richardson 
system. (Annexure III). 80% of these cases are associated with foci of Ductal 
carcinoma in situ. 70 to 80% of these tumors express estrogen and 
progesterone receptors and 15 to 30% of these tumors express Her2neu 
protein.12 
Mixed carcinoma show ductal not otherwise specified pattern in 10 to 
49% of the tumor mass and the rest of tumor show recognized special type. 
Other rare variants of ductal carcinoma NOS include pleomorphic carcinoma 
and those exhibiting osteoclast type of giant cells, choriocarcinomatous 
features and melanotic features. 
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INVASIVE LOBULAR CARCINOMA: 
In 1941, Foote and Stewart et al described the histological features of 
lobular carcinoma in situ and also introduced the term infiltrating lobular 
carcinoma.23 WHO defines this tumor as an invasive carcinoma usually 
associated with lobular carcinoma in situ with more than 90% of tumor mass 
is composed of non cohesive cells individually dispersed or arranged in single 
file linear pattern in a fibrous stroma. These tumors show loss of E cadherin 
expression due to deletion of chromosome 16q. These tumors represent 5 to 
15 % of breast carcinomas. 70 to 80% of these tumors express estrogen 
receptors and 60 to 70% express progesterone receptors.12 
TUBULAR CARCINOMA: 
Fisher et al (1977) was the first to describe the tubular carcinoma of 
breast where the tumor cells form microtubules and also arranged in cords. It 
accounts for 2% of invasive ductal carcinomas. Grossly, these tumors 
measure 0.2 to 2 cm in diameter. Histologically, 90% of tumour mass show 
presence of open tubules lined by a single layer of small and regular epithelial 
cells set in a desmoplastic stroma. These tumors are nearly always show 
positivity for ER, PR and negativity for Her2neu, EGFR.12 
 
INVASIVE CRIBRFORM CARCINOMA: 
These tumors accounts for 0.8 to 3.5% of breast carcinomas. 
Histologically, more than 90% of tumor mass show tumor cells arranged in 
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islands in which well defined spaces are formed by arches of cells (sieve like 
or cribriform pattern). 100% of these tumors show estrogen positivity and 
69% of these tumors show progesterone positivity. 
MEDULLARY CARCINOMA: 
WHO defines this tumor as “well circumscribed carcinoma composed 
of poorly differentiated cells arranged in large sheets, scant stroma and a 
prominent lymphoplasmacytic infiltrate”.  It accounts for 1 to 7% of breast 
cancers. Grossly, it has well defined margins, soft consistency. Histological 
criteria for diagnosis include syncytial growth pattern more than 75%, 
absence of glandular structures, diffuse lymphoplasmacytic infiltrate, marked 
nuclear pleomorphism and complete histological circumscription. Omar 
Hameed et al stated that these tumors usually lack the expression of estrogen 
and progesterone receptors.24 It is frequently associated with BRCA1 and 
TP53 gene mutations. 
MUCINOUS CARCINOMA: 
This tumor accounts for 2% of all breast carcinomas. Grossly, they 
have glistening gelatinous appearance, pushing margins and soft consistency. 
Histologically, it is characterized by proliferation of clusters of uniform round 
cells floating in lakes of extracellular mucin which is mucicarmine positive. 
These tumor cells are typically estrogen positive and 70% show progesterone 
positivity. 
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INVASIVE PAPILLARY CARCINOMA: 
These tumors accounts for less than 1 to 2 % of breast carcinoma. 
Fisher et al first reported that invasive papillary carcinoma is grossly 
circumscribed.25 Microscopically, these tumors are circumscribed with cells 
arranged as delicate or blunt papillae lined by cells with amphophilic 
cytoplasm.100% of these tumors show estrogen positivity and 80% show 
progesterone positivity. 
INVASIVE MICROPAPILLARY CARCINOMA:  
WHO defines this tumor as “carcinoma composed of small clusters of 
tumor cells lying within clear stromal spaces resembling dilated vascular 
channels”. They account for less than 2% of invasive breast cancers. 
APOCRINE CARCINOMA: 
This tumor shows cytological and immunohistochemical features of 
apocrine cells in >90% of the tumor cells. It contains two types of cells – 
Type A cells with abundant granular eosinophilic cytoplasm and Type B cells 
with clear/foamy cytoplasm. Immunohistochemically, they show positivity 
for GCDFP-15 and negative for bcl2 protein, ER and PR.12, 24 
METAPLASTIC CARCINOMA: 
It is a heterogeneous group of neoplasm characterized by intimate 
admixture of adenocarcinoma with dominant areas of spindle, squamous 
and/or mesenchymal differentiation ranging from chondroid and osseous 
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differentiation to frank sarcoma. It account for less than 1% of the breast 
cancers. Grossly, they present as well delineated firm pearly white glistening 
mass. Most of them were estrogen and progesterone receptors negative. 
NEUROENDOCRINE CARCINOMA: 
Primary neuroendocrine carcinomas express features of 
neuroendocrine differentiation such as cell arrangement in solid sheets and 
nests with peripheral pallisading with rare rosette like structures and 
immunocytochemical expression of neuroendocrine markers such as 
chromogranin and synaptophysin in more than 50% of the cell population. 
Most of them were ER and PR positive. 
Other rare variants of breast carcinoma include lipid rich carcinoma, 
Secretory carcinoma, oncocytic carcinoma, adenoid cystic carcinoma and 
acinic cell carcinoma. 
PROGNOSTIC FACTORS: 
Prognostic factor is defined as any variable that provides information 
useful in assessing the outcome at the time of diagnosis of the disease. 
Predictive factor is defined as any variable that predicts the response to a 
given therapy. The prognostic factors are classified as clinical factors, 
morphological factors and genetic/molecular factors. The clinical factors with 
poor prognosis include premenopausal age group, pregnancy, larger tumor 
size, involvement of medial quadrant of breast. The pathological factors play 
more useful role in assessing prognosis.26 It includes the following 
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1. Lymph node status: Metastasis in lymph node is the most important 
prognostic factor. The overall survival rate declines as the number of 
positive nodes increases. Sentinel node is the first lymph node in the 
direct drainage pathway. Sentinel node biopsy plays essential role in 
modern surgery as this node negative patients can be spared the 
morbidity of complete axillary dissection. 
2. Tumor size: Pathological tumor size denotes the measurement of 
invasive component of the tumor. Survival of the patients decrease and 
risk of axillary node metastasis increase with the increase in tumor 
size. 
3. Histological type: Women with tubular, cribriform and mucinous types 
show excellent prognosis with 30 year survival of 60% compared to 20 
% survival of ductal carcinoma NOS patients. 
4. Histological grade: Nottingham modification of Scarf Bloom 
Richardson grading system (Annexure III) classifies breast cancers into 
three groups. Ellis et al reported this grading system to have excellent 
correlation with patients’ survival and rate of metastasis.27 
5. Lymphatic invasion is a poor prognostic factor strongly associated with 
the presence of lymph node metastasis and poor patient survival. 
6. Vascular invasion denotes the infiltration of tumor cells into vascular 
spaces and it predicts the risk of recurrence and visceral metastasis. 
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Other factors reported to have poor prognosis include tumor necrosis, 
lymphocytic infiltration and skin infiltration. The presence of stromal 
elastosis was reported to have favorable prognostic role. Clark et al reported 
the use of Nottingham prognostic index to classify patients of good, 
intermediate and poor prognostic group with annual mortality rate of 3, 7 and 
30%.28 After the advent of Immunohistochemistry and polymerase chain 
reaction, more molecular biomarkers play significant predictive as well as 
prognostic role in breast cancer management. 
Estrogen and progesterone receptors predict response to hormonal 
therapy. 80% of women with ER/PR positive tumors respond to hormone 
therapy compared to 10% response in ER/PR negative subgroup.28 Her 2 neu 
is a transmembrane epidermal growth factor receptor protein also known as c 
erb2. Its overexpression was reported to have poorer outcome and it predicts 
the response to trastuzumab, lapatinib and anthracycline based chemotherapy. 
Recently gene expression profiling has been shown to predict survival, 
recurrence free interval and to identify appropriate therapy for individual 
patients to which they respond better. 
Patients with TP53 mutation were reported to have short survival and 
poor response to treatment. Higher proliferation indices and aneuploid DNA 
status are also assessed to play poor prognostic role in breast cancer patients. 
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IMMUNOHISTOCHEMISTRY: 
Albert Coons et al in 1941 first labeled antibodies directly with 
fluorescent isocyanate. Nakane and Pierce et al in 1966, introduced indirect 
labeling technique in which unlabelled antibody is followed by second 
antibody or substrate. Various stages of development of 
Immunohistochemistry include peroxidase – antiperoxidase method (1970), 
alkaline phosphatase labeling (1971), avidin biotin method (1977) and two 
layer dextrin polymer technique (1993).29 
USES OF IMMUNOHISTOCHEMISTRY IN BREAST PATHOLOGY30 
1. Assessment of Estrogen and Progesterone receptor status using specific 
antibodies to receptor proteins. 
2. Assessment of HER-2 neu protein overexpression using specific 
antibodies to the HER-2 neu protein. 
3. Distinguishing insitu and invasive carcinoma using antibodies to 
myoepithelial markers and basement membrane proteins. 
4. Assessment of metastatic lesions of possible breast origin by using 
antibodies to ER, GCDFP, CK7/CK20 and other markers. 
5. Distinguishing ductal from lobular carcinoma in situ using antibodies to E-
cadherin. 
6. Evaluation of spindle cell lesions to distinguish metaplastic carcinoma 
from mesenchymal lesions. 
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ANTIGEN RETRIEVAL:  
Antigen retrieval can be done by the following different techniques to 
unmask the antigenic determinants of fixed tissue sections. 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Pressure cooker antigen retrieval 
4. Microwave and trypsin antigen retrieval 
PROTEOLYTIC ENZYME DIGESTION: 
Huank et al in 1976 introduced this technique to breakdown formalin 
cross linkages and to unmask the antigen determinants. The most commonly 
used enzymes include trypsin and proteinase.31 The disadvantages include 
over digestion, under digestion and antigen destruction. 
MICROWAVE ANTIGEN RETRIEVAL: 
This is a new technique most commonly used in current practice. 
Microwave oven heating involves boiling formalin fixed paraffin sections in 
various buffers for rapid and uniform heating. Antibodies against Ki67 and 
MIB-1 work well after heat pretreatment in this method.29 
PRESSURE COOKER ANTIGEN RETRIEVAL: 
Miller et al in 1995 compared and proved that pressure cooking 
method has fewer inconsistencies, less time consuming and can be used to 
retrieve large number of slides than in microwave method.32 
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PITFALLS OF HEAT PRETREATMENT: 
Drying of sections at any stage after heat pretreatment destroys 
antigenicity. Nuclear details damage in poorly fixed tissues. Fibers and fatty 
tissues tend to detach from slides while heating. Not all antigens are retrieved 
by heat pretreatment and also some antigens like PGF9.5 show altered 
staining pattern. 
DETECTION SYSTEMS: 
After addition of specific antibodies to the antigens, next step is to 
visualize the antigen antibody reaction complex. The methods employed are 
direct and indirect methods.  
In the direct method, primary antibody is directly conjugated with the 
label. Most commonly used labels are fluorochrome, horse radish peroxidase 
and alkaline phosphatase. Indirect method is a two step method in which 
labeled secondary antibody reacts with primary antibody bound to specific 
antigen. The use of peroxidase enzyme complex or avidin biotin complex 
further increases the sensitivity of immunohistochemical stains.29 
In 1993, Pluzek et al introduced enhanced polymer one step staining, in 
which large numbers of primary antibody and peroxidase enzymes are 
attached to dextran polymer back bone. This is the rapid and sensitive 
method.33 
17 
 
Dextran polymer conjugate two step visualization system is based on 
dextran technology in Epos system. This method has greater sensitivity and is 
less time consuming. 
ESTROGEN RECEPTORS: 
In 1950, Elwood V Jensen et al identified Estrogen receptor34 and in 
1996, Kuiper et al identified Estrogen receptor β gene.35 Estrogen and 
Progesterone receptors are localized in nuclei of approximately 7% of 
epithelial cells of normal breast tissue and it is expressed more in lobular than 
in ductal cells. It shows variation in expression during menstrual period.36 
Estrogen and progesterone receptors belong to super family proteins. 
These nuclear transcription factors are involved in breast development, 
growth and tumorigenesis.35 There are two forms of Estrogen receptors – 
Estrogen receptor α and Estrogen receptor β encoded by 6p25.1 and 14q 
genes respectively.37 Estrogen receptor α is found in endometrium, breast, 
ovarian stroma and hypothalamus. Estrogen receptor β is seen in kidney, 
brain, bone, heart and lungs. Estrogen receptors regulate the expression of 
progesterone and bcl2.35 Walker D et al in 1999 proposed that estrogen 
receptors are cytoplasmic in unliganded state. During activation, estrogen 
receptor diffuses into the cytoplasm and migrates to nucleus. After 
dimerisation of the receptor, it binds to Hormone Responsive Elements in 
DNA and activate MAPK/P13K pathway to induce cell proliferation. 
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Katrina Bauer et al in 2010 studied the ER, PR and HER 2 expression 
in the California Cancer Registry based breast cancer population and 
demonstrated the better five year survival in ER positive group when 
compared to ER negative group.38 
PROGESTERONE RECEPTORS: 
Progesterone receptor is an intracellular steroid receptor that 
specifically binds to progesterone. Progesterone is encoded by PGR gene in 
11q22 gene which is regulated by estrogen receptor. Progesterone binding to 
its receptor results in structural changes to induce cell proliferation. In 1988, 
Clark et al demonstrated progesterone receptor by Immunohistochemistry in 
formalin fixed paraffin embedded sections.39  
SCORING SYSTEM: 
Estrogen and progesterone receptors show nuclear positivity. They are 
scored by the proportion of tumor cells showing positivity and intensity of the 
reaction. Both are summated to give a total score. Different scoring systems 
used to score estrogen and progesterone receptors include H scoring system40, 
Quick scoring system41 and Allred scoring system42. Quick scoring system 
proposed by Barnes et al in 1998 is widely used worldwide as the score 
correlates well with the chance of patient response to endocrine therapy.41 
(Annexure V) 
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Madhuri Kakarala et al (2010) analysed 3,60,933 breast cancer cases in 
American population through SEER program  and reported the higher 
frequency of breast cancers with ER/PR negativity in Asian Indian Pakistani 
women when compared to Caucasian women.43 
HER  2 NEU RECEPTORS: 
HER2 neu (Human Epidermal growth factor Receptor 2) otherwise 
known as c-erbB2 is an oncogene of EGFR family that encodes a 
transmembrane glycoprotein with tyrosine kinase activity. The proto-
oncogene is encoded in 17q11.2 – 12 gene.44Overexpression of this gene has 
been reported in 18 to 30% of breast cancers and is associated with high 
recurrence and worst prognosis.  
Slamon et al (1987) first reported the potential of Her 2 neu to predict 
the time to relapse and overall survival45 using Southern blot technique. 
Berger et al (1988) reported the correlation of Her 2 neu protein 
overexpression with lymph node metastasis and high tumor grade by using 
Immunohistochemistry. Muss et al (1994) reported significant predictive 
value for Her 2 neu overexpression on the response to cytotoxic 
chemotherapy and overall disease outcome. Valone et al46 (1995) reported 
10% response to monoclonal antibody against Her 2 protein in the clinical 
trial study. Cobleigh (1998) demonstrated 15 % response rate for Herceptin 
when used alone in 222 metastatic breast cancer patients.47  
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 Her 2 neu can be assayed by Immunohistochemistry for protein over 
expression and by fluorescent in situ hybridization for gene amplification. 
Recent guidelines48 for reporting Her 2 neu protein expression is given in 
Annexure VI. 
FISH is used as secondary test in equivocal 2+ IHC categories to 
clarify HER2 status of these cases. HER 2 FISH testing results are expressed 
as the ratio of HER2 signals to chromosome 17 signals. The ratio of more 
than 2.2 is considered as positive for amplification.  Other methods of HER 
2 testing techniques include chromogenic in situ hybridization, polymerase 
chain reaction, enzyme linked immunosorbent assay and Southern blotting. 
Over expression of Her 2 neu receptors predicts resistance to treatment 
with alkylating agents and endocrine therapy and predicts response to 
Herceptin therapy and anthracycline based treatments.49  
POLYMERASE CHAIN REACTION: 
PCR is a recently developed procedure for in vitro amplification of 
specific nucleic acid sequence from a complex DNA template in a simple 
enzymatic reaction. In 1971, Gobind Khorona et al described the basic 
principle of replicating a piece of DNA using two primers. In 1983, Kary 
Mullis et al proposed in vitro amplification of piece of DNA using Klenow 
fragment of thermo labile E coli DNA polymerase enzyme from single 
stranded DNA prepared by heat denaturation. But the product was 
incompletely pure with only 1% being target sequence and also there was 
need for addition of enzyme after denaturation step of each cycle.50 
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In 1988, Saiki et al proposed to use thermo stable DNA polymerase 
from thermos aquaticus to withstand repeated heating during consequent 
cycles of amplification. This technique showed increased specificity with 40 
% of amplified DNA fragments showing altered base due to absence of proof 
reading activity. In 1996, Cline J et al developed Pyrococcus furiosus (Pfu) 
DNA polymerase and Thermococcus Litoralis ( VENT) as alternative heat 
stable DNA polymerases with associated 3` to 5` exonuclease activity. This 
technique showed only 3.5% of DNA with altered base. In 1983, Higuchi et al 
first documented real time PCR that enabled the quantification of gene 
expression and DNA copy measurements.51 
The process of PCR requires target DNA, molar excess of 2 
oligonucleotide primers complementary to opposite strands of DNA, heat 
stable DNA polymerases, equimolar mixture of deoxy nucleotide 
triphosphates, Magnesium chloride, potassium chloride, 10mM Tris Hcl 
buffer. PCR cycle consists of 3 steps – denaturation, annealing and extension. 
Denaturation refers to separation of 2 strands of target DNA at 
temperature of 94ºC to 96ºC. The reaction mixture is then cooled to 72ºC to 
permit annealing of oligonucleotide primer to target DNA. The DNA 
polymerase then initiates extension of each primer at its 3` ends. The primer 
extension product is dissociated from target DNA by heating. Each extension 
product as well as original target act as templates for subsequent cycle. At the 
end of each cycle, PCR products are doubled. Thus after n PCR cycles, 2n 
target sequence can be amplified. The whole procedure is carried out in 
thermal cycler that precisely controls the temperature.52 
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Reverse transcriptase PCR is a process developed to amplify RNA 
targets. The complementary DNA is first produced from RNA target by 
reverse transcription and then the cDNA is amplified by PCR. Initially, both 
heat labile avian myeloblastosis virus reverse transcriptase and a thermo 
stable DNA polymerase were used for RT PCR. In 1991, Myers et al. 
proposed the DNA polymerase from Thermus thermophilus can function 
efficiently as both reverse transcriptase and a DNA polymerase.53 
In 1988, Haqqi et al. developed Nested PCR with increased sensitivity 
and specificity. In this method, first primer is used for first round PCR of 15 – 
30 cycles. The products of amplification are then subjected to second round 
amplification with second set of primer which anneal to sequence internal to 
the sequence amplified by the first primer set. In 1988, Chamberlain et al. 
described multiplex PCR where different target sequence can be amplified 
simultaneously in a single reaction using different primers. Competitive PCR 
is a process of co amplification in same reaction tube of 2 different templates 
of equal length and with same primer binding sequences. 
Real time PCR is a technique in which target amplification and 
detection steps occur simultaneously in a same tube. It requires special 
thermal cyclers with precision optics that can monitor the fluorescence 
emission from sample wells through computer software at every cycle. The 
amplification show little change in fluorescence with initial cycles referred as 
baseline plot. Any increase above the baseline indicates detection of 
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accumulated PCR product. The PCR product is detected by using fluorescent 
dyes such as SYBR green I that emit enhanced fluorescence when bound to 
double stranded DNA. The PCR product can also be detected using 
hybridization probes such as Taqman probe, FRET probe, molecular beacon 
or dark quencher probe.53  
In 1991, Wittwer et al. introduced rapid cycle PCR where thin walled 
tubes or capillaries are used to enable rapid thermal transfer rate. It 
incorporates 35 to 100 nucleotides / second. In case of mRNA quantification, 
gene expression has to be related to some house keeping genes that are 
expressed throughout the cells such as GADPH, β actin or PGP9.5.54  
Advantages of PCR include high speed, ease of use, high sensitivity 
and ability to amplify DNA from formalin fixed paraffin embedded tissue 
samples. A limitation of PCR is that only 0.1 – 5 kb size DNA sequences can 
be amplified. The amplification product levels off due to finite enzyme.  
HIERARCHICAL MODEL OF BREAST EPITHELIUM: 
Molecular studies support the hierarchical arrangement of human 
breast epithelial cells. The stem cell gives rise to committed progenitor cells 
for either the myoepithelial or luminal epithelial lineages. The luminal 
progenitor subpopulation can commit to either a ductal or alveolar cell fate, 
depending on the developmental stage (puberty or pregnancy).  Stem like 
cells in the human breast have an asymmetric distribution, primarily restricted 
to the ducts rather than lobules.55 
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MOLECULAR SUBTYPES OF BREAST CANCER 
The histological appearances of tumors cannot fully reveal the 
underlying complex genetic alterations and biologic events involved in their 
development and progression. This promoted the development of a new 
classification based on key molecular events involved in process of 
carcinogenesis, thereby providing a molecular explanation for the different 
morphologic phenotypes and behavior.  
On the basis of recent DNA microarray studies, Sorley et al identified 
distinct molecular subtypes of breast carcinoma on the basis of gene 
expression profiling. These include the luminal A, luminal B, basal-like, Her2 
overexpressing and claudin-low normal-breast-like subtypes. The differences 
in tumor subtypes are hypothesized to reflect different mutation profiles, as 
well as differences in the cell of origin.5 (Figure 1)  
Large scale gene expression profiling from formalin fixed, paraffin 
embedded samples is not feasible. Therefore, immunohistochemical markers 
have been used as surrogates for DNA microarray in subtyping breast cancers. 
Nielsen et al was the first to define IHC subtypes using four antibody panel 
including ER, HER1, HER2 and CK5/6.56 Carey et al. updated IHC subtype 
definition as luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or 
PR+, HER2+), HER2 (ER-, PR-, HER2+), basal like (ER-, PR-, HER2-, 
CK5/6+) and unclassified (ER-, PR-, HER2-, CK5/6-, HER1-).10 These 
molecular differences correlate with clinical features such as survival, 
prognosis and treatment sensitivity. 
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Common types of invasive ductal and invasive lobular carcinomas, 
display evidence of luminal cell differentiation. Luminal A and B subtypes 
are generally associated with a good prognosis.  
Tumors that over express HER2 (or exhibit amplification) usually 
display luminal features, but are associated with poor overall survival.57 These 
tumors have a distinct molecular profile and aggressive clinical course 
associated with the propensity to develop metastasis in brain.58 
The basal-like subtype is very heterogeneous and comprises 15%–20% 
of breast cancers.59 This group of tumors is the most clinically aggressive and 
tends to exhibit a triple-negative phenotype (i.e., lack expression of ER, PR, 
and HER2). In combination with EGFR and cytokeratin 5/6, these markers 
provide high specificity in identifying basal-like tumors.60 Carey et al in 2006 
studied 496 invasive breast cancer cases from California breast cancer study 
and demonstrated poor ten year survival of basal like and HER2 molecular 
type patients when compared to luminal type patients.10 
ROLE OF GENES IN MAMMARY GLAND DEVELOPMENT & 
CARCINOGENESIS:                                            
Pietersen and co-workers described the expression of Bmi1 in all 
mammary epithelial cells and its role in regulating stem cell proliferation but 
opposing its differentiation.61 NOTCH signaling pathway regulates the 
mammary cell fate decisions. NOTCH4 gene directs progenitor cells to 
myoepithelial cell commitment. NOTCH3 direct progenitor cells to luminal 
cell commitment.62 Gata3 controls differentiation along the ductal and 
alveolar luminal lineages. 
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In hereditary breast cancers, deletion of a allele of BRCA1 and in 
sporadic cancers, activation of other pathways such as Notch, Hedgehog, Wnt 
or amplification of Her 2 neu or deletion of PTEN lead to dysregulation of 
stem cell self renewal. These aberrant stem cells are targets for further 
carcinogenic mutations.21(Figure 2) 
Liu et al demonstrated that hedgehog signaling acting through BMI1 
regulates the self-renewal of both normal and malignant human mammary 
stem cells. This process is blocked by specific inhibitors such as 
cyclopamine.63 
ROLE OF BMI 1 GENE IN BREAST CANCERS: 
B-cell-specific Moloney murine leukemia virus insertion site 1 gene    
(Bmi-1) is a transcriptional repressor that belongs to the polycomb-group 
family of proteins involved in hematopoiesis and regulation of proliferation. 
Bmi-1 is proved to be expressed in various human malignant tumors such as 
brain tumors, breast cancers, leukemia and also gastric cancers.64  
Hyun Jo Youn et al (2005) suggested cell cycle deregulation by Bmi 1 
gene alteration to play a role in lymph node metastasis of breast cancer 
patients.65 Silva et al (2007) demonstrated poor overall and disease free 
survival in breast cancer patients with circulating Bmi-1 mRNA.66 Young Jin 
Choi et al (2007) found Bmi-1 protein to be associated with favorable survival 
in ER positive breast cancer patients.67  
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In breast Bmi-1 acts as the critical regulator of stem cell self renewal 
and also maintains the proliferation of committed mammary progenitor 
cells.63 Bmi-1 gene repress INK4a/ARF locus, which encodes two tumor 
suppressors (p16 & p19) and activates human telomerase reverse 
transcriptase, which extend the replicative life span and immortalize the 
cells.68 The longevity of many adult stem cells and restricted progenitors 
makes them likely candidates for accumulating genetic mutations. These 
aberrant stem cells are highly resistant to all the current adjuvant therapies 
such as chemotherapy, radiation therapy and hormonal therapy. Newer 
treatment approaches to target this stem cell population is the emerging need 
of this era.  
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MATERIALS AND METHODS 
This study is a retrospective descriptive study of invasive breast 
cancers conducted in the Institute of Pathology, Madras Medical College and 
Government hospital, Chennai during the period between July 2008 and May 
2010.   
Source of data: 
The invasive ductal carcinoma cases reported in mastectomy specimen 
received in the Institute of pathology, Madras Medical College between July 
2008 to May 2010 from the Department of Surgery, Oncology, Plastic surgery 
and Geriatrics, Government General Hospital. A total of 238 mastectomy 
specimens (simple, modified radical or radical mastectomy) were received 
during this period. 
Inclusion criteria 
All the invasive ductal carcinoma cases reported in mastectomy 
specimens irrespective of the age and sex were included for the study. 
Exclusion criteria 
• Non neoplastic lesions and benign tumors of breast. 
• Ductal carcinoma breast reported in incision/excision biopsy and 
completion mastectomy specimens. 
• Cases with inadequate material from the tumor for doing both 
immunohistochemistry and polymerase chain reaction were not 
included in the study. 
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METHOD OF DATA COLLECTION: 
 Detailed history of the cases regarding age, sex, menstrual history, side 
of the breast, type of procedure, history of neo adjuvant therapy, details of 
gross characteristics such as tumor size, nodal status details were obtained  for 
all the 238 mastectomy cases reported during the period from Surgical 
Pathology records. Freshly cut and Hematoxylin Eosin stained 4 µ thick 
sections of the paraffin tissue blocks of mastectomy specimens were reviewed 
and graded using the Nottingham modification of the Scarf Bloom Richardson 
Grading system (Annexure III) and they are further evaluated for the presence 
of necrosis, lymphocytic response and lymphovascular invasion by tumor. 20 
cases of each grade from Invasive ductal carcinoma NOS subtype were 
randomly selected from the total cases and their representative formalin fixed 
paraffin embedded tissue samples were subjected to Immunohistochemistry 
for a panel of 4 markers and to real time reverse transcriptase polymerase 
chain reaction for gene analysis. The results were recorded with photographs.  
Follow up data of breast cancer patients regarding the adjuvant therapy, dose, 
duration, recurrence, disease free survival were obtained from Medical 
Records Section of Department of Oncology. 
IMMUNOHISTOCHEMICAL EVALUATION: 
Immuohistochemical analysis of a panel of markers including estrogen 
receptor, progesterone receptor, Human epidermal growth factor receptor 2 
(Her 2 neu) and Cytokeratin 5/6 were done in paraffin embedded tissue 
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samples using Supersentive polymer HRP system based on non biotin 
polymeric technology. Due to economic constraints, immunohistochemistry 
for Cytokeratin 5/6 was done only in triple negative cases to differentiate 
between basal and unclassified subtypes of breast cancer. 
4 µ thick sections from selected formalin fixed paraffin embedded 
tissue samples were transferred onto gelatin coated slides. Heat induced 
antigen retrieval was done. The antigen is bound with mouse monoclonal 
antibody (Biogenex) against Estrogen and Progesterone receptors, 
Cytokeratin 5/6 and rabbit monoclonal antibody against Her2 neu protein and 
then detected by the addition of secondary antibody conjugated with horse 
radish peroxidase-polymer and Diaminobenzidine substrate. The step by step 
procedure of Immunohistochemistry is given in Annexure IV. 
Antigen Vendor Species Dilution Positive control 
ER BIOGENEX Mouse Ready to use Breast 
PR BIOGENEX Mouse Ready to use Breast 
Her 2 neu BIOGENEX Rabbit Ready to use 
Breast 
cancer 
Cytokeratin 5/6 LABVISION Mouse 1:50 skin 
 
INTERPRETATION & SCORING SYSTEM: 
The immunohistochemically stained slides were analyzed for the 
presence of reaction, cellular localization (nuclear/cytoplasmic /membranous / 
combinations), percentage of cells stained and intensity of reaction. Nuclear 
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staining was assessed for ER and PR, membranous staining for Her 2 neu and 
cytoplasmic staining was assessed for CK5/6. Immunohistochemical scoring 
for estrogen and progesterone receptors were done with Quick score 
(Annexure V). Her2neu scoring was done as per recent ASCO CAP 
guidelines (Annexure VI). In this study, Her 2 neu score of 0 and 1+ were 
considered as negative and score 2+ and 3+ were considered as positive. An 
estimation of more than 10 % of tumor cells with cytoplasmic staining is 
considered as positive reaction for CK5/6. 
IHC SUBTYPING CRITERIA 
The IHC-based definition of breast cancer subtypes used in this study 
was as follows: Luminal A (ER+ and/or PR+, HER2 -), Luminal B (ER+ 
and/or PR+, HER2+), HER2 (ER-, PR-, HER2+), basal-like (ER-, PR-, 
HER2-, CK5/6+) and unclassified (negative for all markers). 
REAL TIME POLYMERASE CHAIN REACTION: 
ISOLATION OF TOTAL RNA: 
10 sections of 10µ thickness were collected from all the formalin fixed 
paraffin embedded tissue samples. The total RNA from the samples were 
purified with RNeasy kit (Qiagen) and stored in collection tubes at -20ºC to -
70ºC. (Step by step procedure given in appendix VII). The concentration of 
total RNA isolated from each sample was estimated using Eppendorf 
Biophotometer. The volume of each sample containing 5ng of total RNA was 
calculated. 
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REAL TIME PCR AMPLIFICATION: 
The real time one step polymerase chain reaction is carried out with 
Rotor Gene Q system using Rotor gene SYBR green RT PCR kit. Normal 
breast tissues obtained from autopsy material were used as controls to study 
the relative gene expression in breast cancer. β actin 1 (ACTB1) is used as 
house keeping gene in this study. Samples were run in duplicates for both 
BMI1 and ACTB1 gene. 
To check the efficiency of the RT PCR a standard curve with log 
concentration obtained by dilution of control sample was generated for both 
BMI1 and ACTB1 gene simultaneously. The concentration dilutions were 
100ng, 10ng and 1 ng respectively. 
BMI 1 gene and β actin gene were amplified using the extracted RNA 
as templates and the following forward and reverse primers. 
BMI1 forward (5’ GCTTCAAGATGGCCGCTTG 3’) primers, 
BMI1 Reverse (5’ TTCTCGTTGTTCGATGCATTTC 3’) primers, 
β actin forward (5'CCCCTGGCCAAGGTCATCCATGACAACTTT-3') primers& 
β actin reverse (5'GGCCATGAGGTCCACCACCCTGTTGCTGTA-3') primers. 
The Polymerase chain reaction was carried out as follows, 
• Thaw 2x Rotor gene SYBR green RT PCR master mix, template RNA, 
primer and RNAse free water to prevent premature complementary 
DNA synthesis. 
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• The reaction mix was prepared in PCR tubes as follows 
 2xRotor gene SYBR green RT PCR master mix - 12.5 ml 
 Rotor gene RT mix                                               - 0.25 ml 
 Primer for BMI 1/β actin                                      - 2.5 ml 
 Template RNA of each sample with concentration of 5 ng 
 The total reaction volume was made into 25 µl with RNAse free 
water. 
• The PCR tubes were placed in Rotor Gene cycler and the cycling 
conditions were programmed as follows 
STEP TEMPERATURE TIME 
Reverse transcription 55ºC 10 minutes 
PCR Initial activation step 95ºC 5 minutes 
One step PCR cycling x 40 cycles 
Denaturation 95ºC 5 seconds 
Combined annealing/extension 60ºC 10 seconds 
 
• Melting curve analysis was performed at the end of reactions with 
temperature range of 55ºC to 95ºC to check the specificity of the 
reaction. 
RELATIVE GENE EXPRESSION ANALYSIS: 
The BMI1 RNA levels were calculated in the breast cancer samples 
and normal breast tissue in a relative quantification approach by using a 
reference gene ACTB1. Relative expression was calculated by deriving the 
delta delta CT values for BMI1 with reference to ACTB1 gene expression. 
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These values were generated automatically by Rotor Gene Q 2 Plex series 
software version 1.74. Relative concentration of BMI1 RNA in tumor samples 
to that of control samples was calculated as a linear value from the equation 
 2-Δ Δ CT . These values were subjected to statistical analysis. 
STATISTICAL ANALYSIS: 
The statistical analysis is performed using statistical package for social 
science software version 11.5. Correlation between Her2 neu expression and 
clinicopathological prognostic factors such as tumor size, nodal status, 
necrosis and lymphovascular invasion was analyzed using Pearson chi square 
test. 
The efficiency of the real time PCR experiment derived from standard 
curve was within a range of 0.82 and 0.86 for BMI1 and ACTB1 reference 
genes respectively elucidating the validity of experiment. Standard curve from 
first set was used for the other set runs subsequently. Melt curve analysis 
showed minimized range of primer dimmers with peaks at 75ºC.  
The expression of BMI 1 gene was non parametric, so the correlation 
with other prognostic factors was done using Mann Whitney U test, student t 
test and Pearson correlation co efficient analysis.  
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OBSERVATION AND RESULTS 
In the study period of 23 months from July 2008 to May 2010, a total 
of 16,028 specimens were received in the Institute of Pathology, Madras 
Medical College for histological examination. Total numbers of breast 
specimens received were 969 cases, of these breast tumors accounted for 676 
cases with a percentage of 4.22 %. The relative frequency of breast cancers 
among the specimen received was 2.1%. The total number of non neoplastic, 
benign and malignant cases was 293, 325 and 351 respectively. Thus the 
distribution of non neoplastic breast lesions were 30.24 %, of benign tumors 
were 33.54% and of malignant tumors were 36.22%. Breast cancers had a 
peak incidence in the age group of 41-50 years. (Table 1 and Chart 1) 
TABLE 1 AGE WISE DISTRIBUTION OF BREAST CANCERS 
AGE GROUP NUMBER OF CANCERS PERCENTAGE 
21 – 30 years 12 5% 
31 – 40 years 52 22% 
41 – 50 years 89 38% 
51 – 60 years 48 20% 
61 – 70 years 29 12% 
More than 70 years 8 3% 
Total cases 238 100% 
 
The youngest age of presentation of breast cancer is at 25 years in this 
study. The distribution of histological subtypes of breast carcinoma is shown 
in Table 2 & Chart 2. 
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TABLE 2 DISTRIBUTIONS OF HISTOLOGICAL SUBTYPES OF 
BREAST CANCERS 
 
S.No Histological subtypes Number of cases Percentage 
1 Invasive ductal carcinoma NOS 205 86.13% 
2 Invasive lobular carcinoma 3 1.26% 
3 Mucinous carcinoma 10 4.20% 
4 Papillary carcinoma 6 2.52% 
5 Micropapillary carcinoma 2 0.84% 
6 Medullary carcinoma 1 0.42% 
7 Cribriform carcinoma 2 0.84% 
8 Metaplastic carcinoma 3 1.26% 
9 Mixed carcinoma 4 1.68% 
10 Adenoid cystic carcinoma 1 0.42% 
11 Apocrine carcinoma 1 0.42% 
12 Total number of cases 238 100% 
 
Among the 238 cases, 235 (99%) cases were reported in females and 3 
(1%) cases were reported in male breast. (Table 3 & Chart 3)  
TABLE 3 SEX DISTRIBUTION IN INVASIVE DUCTAL 
CARCINOMA 
 
SEX TOTAL NUMBER OF CASES PERCENTAGE 
Male 3 1% 
Female 235 99% 
Total 238 100% 
 
116 cases of Invasive ductal carcinoma were reported in left breast, 
122  cases were reported in right breast and 1 case had cancer in both the 
breasts. (Table 4 and Chart 4) 
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TABLE 4 DISTRIBUTION OF SIDE OF INVOLVEMENT IN BREAST 
CARCINOMA 
 
SIDE OF BREAST CANCER NUMBER OF CASES PERCENTAGE
Left 117 49.1% 
Right 120 50.5% 
Both breasts 1 0.4% 
Total cases 238 100% 
 
56 cases (23%) had tumor less than 2 cm in size, 123 cases (52%) were 
of 2 to 5 cm in size and 59 cases (25%) were more than 5 cm in size.  
(Table 5 & Chart 5) 
TABLE 5 - DISTRIBUTION OF SIZE IN INVASIVE DUCTAL 
CARCINOMA 
 
SIZE OF TUMOUR NUMBER OF CASES PERCENTAGE 
<2 cm (T1) 56 23% 
2-5 cm (T2) 123 52% 
>5 cm (T3) 59 25% 
 
There were  206 Invasive ductal carcinoma NOS type breast cancers in 
the study sample which were graded according to Modified Scarf Bloom 
Richardson grading system (Annexure II) out of which 60 cases(29.12%) 
were in grade I, 109 cases (52.92%) were in grade II and 37cases (17.96%) 
were in grade III. (Table 6 & Chart 6) 
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TABLE 6 DISTRIBUTION OF HISTOLOGICAL GRADE IN 
INVASIVE DUCTAL CARCINOMA NOS TYPE 
 
GRADE NUMBER OF CASES PERCENTAGE 
GRADE I 60 29.12% 
GRADE II 109 52.92% 
GRADE III 37 17.96% 
TOTAL 206 100% 
 
68 cases (29%) had up to 3 nodes with metastatic ductal carcinomatous 
deposit, 50 cases (21%) had 4 to 10 involved nodes, 5 cases (2%) had more 
than 10 involved nodes while 115 cases (48%) had no lymph node 
involvement. (Table 7 & Chart 7) 
 
TABLE 7 DISTRIBUTION OF LYMPH NODE METASTASIS IN 
BREAST CANCERS 
 
LYMPH NODE STATUS NUMBER OF CASES PERCENTAGE 
Negative 115 48% 
1 - 3 positive nodes 68 29% 
4 – 10 positive nodes 50 21% 
>10 positive nodes 5 2% 
Total 238 100% 
 
137 cases (58%) had lymphatic invasion as against 101cases (42%) 
without lymphatic invasion. (Table 8 & Chart 8) 
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TABLE 8 DISTRIBUTION OF LYMPHATIC INVASION IN 
INVASIVE DUCTAL CARCINOMA BREAST 
 
LYMPHATIC INVASION NUMBER OF CASES PERCENTAGE
Present 137 58% 
Absent 101 42% 
Total 238 100% 
 
52 cases (22%) showed vascular invasion while 186 cases (78%) cases 
had no vascular invasion. (Table 9 & Chart 8) 
 
TABLE 9 DISTRIBUTION OF VASCULAR INVASION IN INVASIVE 
DUCTAL CARCINOMA BREAST 
 
VASCULAR INVASION NUMBER OF CASES PERCENTAGE 
Present 52 22% 
Absent 186 78% 
Total 238 100% 
 
17 % of the cases had skin infiltration (Table 10), 65% of the cases had 
lymphocytic infiltration (Table 11), 48% of the cases had necrosis (Table 12) 
as shown in Chart 9. 
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TABLE 10 DISTRIBUTION OF SKIN INFILTRATION IN INVASIVE 
DUCTAL CARCINOMA BREAST 
 
SKIN INFILTRATION NUMBER OF CASES PERCENTAGE 
Present 41 17% 
Absent 197 83% 
Total 238 100% 
 
TABLE 11 DISTRIBUTION OF LYMPHOCYTIC INFILTRATION IN 
INVASIVE DUCTAL CARCINOMA BREAST 
 
LYMPHOCYTIC 
INFILTRATION 
NUMBER OF 
CASES 
PERCENTAGE
Present 151 65% 
Absent 83 35% 
Total 238 100% 
 
TABLE 12 - DISTRIBUTION OF NECROSIS IN BREAST CANCER 
NECROSIS NUMBER OF CASES PERCENTAGE 
Absent 124 52% 
Present 114 48% 
Total 238 100% 
 
RESULTS OF IMMUNOHISTOCHEMICAL AND MOLECULAR 
STUDIES 
In this study, 41% expressed positive reaction for estrogen receptors, 
51% expressed positive reaction for progesterone receptors and 30% showed 
Her 2 neu over expression. (Table 13 & Chart 10) 
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TABLE 13 - DISTRIBUTION OF HORMONE RECEPTORS AND HER 
2 NEU EXPRESSION IN INVASIVE DUCTAL CARCINOMA NOS 
 
IHC PARAMETER POSITIVE (%) NEGATIVE (%) 
Estrogen receptor 25 (41%) 35 (59%) 
Progesterone receptor 31 (51%) 29 (49%) 
Her 2 neu 18 (30%) 42 (70%) 
 
Estrogen receptors were expressed in 80% of grade 1, 35% of grade 2 
and 10% of grade 3 tumors while progesterone receptors were expressed in 
80% of grade 1, 65% of grade 2  and 10% of grade 1tumors. Thus the receptor 
status was found to be comparatively reduced with increasing grade of the 
breast cancer. (Table 14 & Chart 11) 
TABLE 14 - DISTRIBUTION OF HORMONE RECEPTORS IN 
DIFFERENT GRADES OF INVASIVE DUCTAL CARCINOMA NOS 
 ER POSITIVE PR POSITIVE 
Grade  I 16 16 
Grade  II 7 13 
Grade  III 2 2 
 
The mean quick score for estrogen receptors was found to be 5 for 
grade 1, 1.55 for grade 2 and 0.45 for grade 3 while for progesterone 
receptors, it was found to be 4.9 for grade 1, 2.9 for grade 2 and 0.45 for 
grade 3 cases respectively. (Chart 12) 
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TABLE 15 DISTRIBUTION OF QUICK SCORE Vs GRADE  
OF BREAST CANCER 
 MEAN ER QUICK SCORE 
MEAN PR QUICK 
SCORE 
GRADE I 5 4.9 
GRADE II 1.55 2.9 
GRADE III 0.45 0.45 
 
TABLE 16 DISTRIBUTION OF MOLECULAR SUBTYPES IN 
INVASIVE DUCTAL CARCINOMA NOS TYPE 
MOLECULAR 
SUBTYPE 
NUMBER OF 
CASES PERCENTAGE 
LUMINAL A 27 45% 
LUMINAL B 7 12% 
HER 2 TYPE 11 18% 
BASAL 5 8% 
UNCLASSIFIED 10 17% 
 
Molecular subtyping of breast cancers was done in accordance with 
Carey et al10.  27 cases (45%) were luminal A type, 7 cases (12%) were 
luminal B type, 11 cases(18%) were Her 2 type, 5 cases (8%) were basal type 
and 10 cases (17%) were of unclassified type. (Table 16 & Chart 13) 
CORRELATION OF HER 2 NEU WITH OTHER PROGNOSTIC 
FACTORS: 
Her 2 neu over expression was noted in 30.4% of premenopausal 
women and 30.5% of postmenopausal women. There was no significant 
correlation between the menstrual status and Her 2 neu over expression. 
(Table 17 & Chart 14) 
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TABLE 17 CORRELATION OF MENSTRUAL STATUS  
WITH HER 2 NEU EXPRESSION 
Menstrual status Her 2 neu positive (%) 
Her 2 neu 
negative (%) Total
Pearson chi 
square test 
Premenopausal 7(30.4%) 16(69.6%) 23 χ2=0.01 P=0.99 
Postmenopausal 11(30.5%) 25(69.5%) 36 
 
Her 2 neu oncoprotein expression was noted in 33.33% of T1 size 
tumors, 25% of T2 size tumors and 36.84% of T3 size tumors. There was no 
significant correlation between the tumor size and Her 2 neu over expression. 
(Table 18 & Chart 15) 
TABLE 18 CORRELATION OF TUMOR SIZE AND  
HER 2 NEU EXPRESSION 
Average size Her 2 neu positive (%) 
Her 2 neu 
negative (%) Total 
Pearson chi 
square test 
<2 cm (T1) 3(33.33%) 6(66.67%) 9 χ2=0.85 
P=0.65 
2 -5 cm (T2) 8(25%) 24(75%) 32 
>5 cm (T3) 7(36.84%) 12(63.16%) 19 
 
Her 2 neu overexpression was noted in 31.57% of nodal metastasis 
positive group as against 27.27% of nodal metastasis negative group. 
Receptor positivity increases with nodal metastasis but no significant 
correlation was found in statistical analysis. (Table 19 & Chart 16) 
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TABLE 19 CORRELATION OF NODAL METASTASIS AND 
 HER 2 NEU EXPRESSION 
Nodal 
metastasis 
Her 2 neu positive 
(%) 
Her 2 neu 
negative (%) Total 
Pearson chi 
square test 
Present  6(31.57%) 16(68.43%) 22 χ2=0.01 
P=0.99 Absent  12(27.27%) 26(72.73%) 38 
 
5% of grade 1, 55% of grade 2 and 30% of grade 3 tumors were found 
to be positive for Her 2 neu oncoprotein expression (Table 20 & Chart 17). 
This explained the higher receptor expression in higher grade tumors and the 
association was found to be statistically significant.(p=0.003). 
 
TABLE 20 CORRELATION OF GRADE AND  
HER 2 NEU EXPRESSION 
Grade Her 2 neu positive (%) 
Her 2 neu negative 
(%) 
Pearson chi square 
test 
Grade 1 1(5%) 19(95%) 
χ2=0.85 P=0.65 Grade 2 11(55%) 9(45%) 
Grade 3 6(30%) 14(70%) 
 
There was no statistically significant association noted between Her 2 
neu oncoprotein overexpression and other prognostic factors such as skin 
infiltration, lymphatic invasion, vascular invasion, lymphocytic infiltration 
and necrosis as shown in Table 21. 
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TABLE 21 CORRELATION OF HER 2 NEU WITH OTHER 
HISTOLOGICAL PROGNOSTIC FACTORS 
Patient characteristics HER2NEU Pearson chi square test Negative Positive
Skin infiltration 
Present 9 6 χ2=0.95 P=0.33 
Absent 33 12 
Lymphatic invasion 
Present 25 12 χ2=0.27 P=0.60 
Absent 17 6 
Vascular invasion 
Present 14 3 χ2=1.72 P=0.19 
Absent 28 15 
Lymphocytic infiltration 
Absent 10 4 χ2=0.02 P=0.89 
Present 32 14 
Necrosis 
Present 29 14 χ2=0.49 P=0.69 
Absent 13 4 
 
Her 2 neu overexpression was noted in 12% of ER positive group as 
opposed to 42.85% of ER negative group (Table 22 & Chart 18). There was 
inverse relationship between estrogen receptor expression and Her 2 neu 
protein expression and the correlation was found to be statistically significant. 
(p=0.01) 
TABLE 22 CORRELATION OF ESTROGEN RECEPTOR STATUS 
AND HER 2 NEU EXPRESSION 
ER status 
Her 2 neu 
positive (%) 
Her 2 neu 
negative (%)
Total 
Pearson chi 
square test 
Positive 3(12%) 22(88%) 25 χ2=6.61 
P=0.01** Negative 15(42.52%) 20(57.48%) 35 
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Her 2 neu receptor positivity was observed in 19.35% of PR positive 
group as against 41.37% of PR negative group (Table 23 & Chart 19). Thus 
there was inverse relationship between progesterone receptor and Her 2 neu 
overexpression and the negative correlation was found to be statistically 
significant. (p=0.05) 
TABLE 23 CORRELATION BETWEEN PROGESTERONE 
RECEPTOR AND HER 2 NEU EXPRESSION 
 
PR status 
Her 2 neu 
positive (%) 
Her 2 neu 
negative (%) 
Total 
Pearson chi 
square test 
Positive 6(19.35%) 25(80.65%) 31 χ2=3.81 
P=0.05* Negative 12(41.37%) 17(58.63%) 29 
 
CORRELATION OF BMI 1 GENE EXPRESSION WITH OTHER 
KNOWN PROGNOSTIC FACTORS 
Bmi-1 gene was upregulated in 12 cases while downregulated in 47 
cases. Table 24 and Chart 20 shows increased mean relative concentration of 
Bmi 1 gene in premenopausal women as opposed to lesser relative 
concentration in postmenopausal women. The correlation was found to be 
statistically significant.   
TABLE 24 CORRELATION OF MENSTRUAL STATUS AND BMI 1 
GENE EXPRESSION 
Menstrual 
status 
N 
Mean relative 
concentration of Bmi 1 
mRNA 
Standard 
Deviation 
Mann 
whitney U 
test 
Premenopausal 23 4.68 13.38 Z=1.96 
P=0.05* Postmenopausal 36 1.97 6.45 
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The mean relative concentration of Bmi 1 mRNA was higher in small 
size tumors when compared to large size tumors. The correlation was found to 
be statistically significant (p=0.007). (Table 25 & Chart 21) 
TABLE 25 CORRELATION OF TUMOR SIZE AND  
BMI 1 GENE EXPRESSION 
Size N Mean relative concentration of Bmi 1 mRNA 
Standard 
Deviation 
Kruskal 
wallis H test
<2 cm 9 12.0084700 21.74571466 
Z=9.79 
P=0.007** 
2 to 5 cm 32 0.5752878 1.54953139 
>5 cm 19 2.7442032 6.37071976 
Total 60 3.19 9.972 
 
The relative expression of Bmi 1 mRNA was higher in patients with 
axillary node metastasis but the correlation was not statistically significant 
(Table 26 & Chart 22). 
TABLE 26 CORRELATION OF NODAL METASTASIS AND BMI 1 
GENE EXPRESSION 
Lymph node 
metastasis N 
Mean relative 
concentration of Bmi 1 
mRNA 
Standard 
Deviation 
Mann 
whitney U 
test 
Absent 22 0.5188127 1.49036185 Z=0.92 
P=0.35 Present 38 4.4003005 11.91313924
 
Higher concentration of Bmi 1 mRNA was found in grade 3 tumors 
when compared to grade 1 tumors but the correlation was not statistically 
significant. (Table 27 & Chart 23) 
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TABLE 27 CORRELATION OF GRADE AND BMI 1 GENE 
EXPRESSION 
Grade N Mean relative concentration of Bmi 1 mRNA SD 
Kruskal wallis 
H test 
1 17 2.09 5.852 
Z=1.77 P=0.41 
2 19 2.40 7.907 
3 20 4.87 13.970
Total 56 3.19 9.972 
 
There was no statistically significant correlation between the Bmi 1 
mRNA concentration and other prognostic factors such as skin infiltration, 
lymphatic invasion, vascular invasion, lymphocytic infiltration and 
necrosis.(Table 28) 
TABLE 28 CORRELATION OF BMI 1 GENE AND OTHER 
HISTOLOGICAL PROGNOSTIC FACTORS 
Tumor  characteristics N Mean SD 
Mann whitney U 
test 
Skin infiltration 
Absent 45 2.74 9.75 
Z=0.33 P=0.79 
Present 15 3.69 9.69 
Lymphatic invasion 
Absent 23 2.65 8.43 
Z=0.97 P=0.33 
Present 37 3.18 10.46
Vascular invasion 
Absent 43 2.32 6.80 
Z=0.14 P=0.89 
Present 17 4.64 14.79
Lymphocytic infiltration 
Absent 14 4.92 10.69
Z=0.54 P=0.88 
Present 46 2.39 9.37 
Necrosis 
Absent 17 2.58 6.74 
Z=1.32 P=0.18 
Present 43 3.14 10.67
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TABLE 29 CORRELATION OF ESTROGEN RECEPTOR AND BMI 1 
GENE EXPRESSION 
ER N 
Mean relative 
concentration of Bmi 1 
mRNA 
Standard 
Deviation 
Mann whitney U 
test 
Negative 35 4.20 11.969 
Z=1.98 P=0.05* 
Positive 25 1.51 5.020 
 
Table 29 shows higher concentration of Bmi 1 mRNA in estrogen 
receptor negative group when compared to estrogen receptor positive group. 
The inverse correlation between the estrogen receptor status and Bmi 1 gene 
expression was found to be statistically significant (p=0.05) (Chart 24) 
Higher mean relative concentration of Bmi 1 mRNA was found in 
progesterone receptor positive group when compared to progesterone receptor 
negative group but the correlation was not statistically significant. (Table 30 
& Chart 25) 
TABLE 30 CORRELATION OF PROGESTERONE RECEPTOR AND   
BMI 1 GENE EXPRESSION 
PR N 
Mean relative 
concentration of Bmi 1 
mRNA 
Standard 
Deviation 
Mann whitney U 
test 
Negative 29 2.26 6.666 
t=0.71 P=0.47 
Positive 31 4.19 12.669 
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Higher mean Bmi 1 mRNA concentration was associated with Her 2 
neu negative group when compared to that of Her 2 neu positive group. The 
inverse correlation was found to be statistically significant (p=0.05). (Table 
31 & Chart 26) 
TABLE 31 CORRELATION OF HER 2 NEU AND BMI 1 GENE 
EXPRESSION 
HER2NEU N 
Mean relative concentration 
of Bmi 1 mRNA 
SD 
Mann whitney U 
test 
Negative 38 3.52 10.826
Z=1.97P=0.05 
Positive 18 2.50 8.118 
 
TABLE 32 CORRELATION ANALYSIS OF BMI 1 GENE WITH 
KNOWN PROGNOSTIC FACTORS 
BMI 1 gene Age Size Grade Node status ER PR HER2NEU
Pearson 
Correlation 
-.108 -.230 0.132 0.054 -.113 -.014 -0.060 
Sig. (2-tailed) .413 .05* 0.316 0.681 .388 .915 0.651 
 
Interpretation for r-value 
Pearson correlation coefficient is denoted by “r”. “r” always lies between -1  
to  +1  
0.0 – 0.2    poor correlation 
0.2 - 0.4    fair correlation 
0.4 - 0.6    moderate correlation 
0.6 – 0.8    substantial correlation 
0.8 - 1.0     strong correlation 
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TABLE 33 CORRELATION OF MOLECULAR SUBTYPES OF 
INVASIVE DUCTAL CARCINOMA NOS AND BMI 1 GENE 
EXPRESSION 
Subtype N Mean Std. Deviation Kruskal wallis H test 
Luminal A 27 3.9531744 12.70713437 
Z=9.99 P=0.05* 
Luminal B 7 0.9897729 1.86134640 
Basal 5 2.7824000 4.15567357 
HER 11 3.4577845 10.36134463 
Unclassified 10 1.3013550 2.62116660 
Total 60 2.9770883 9.66183337 
 
The higher mean relative concentration of Bmi 1 mRNA was 
associated with luminal A subtype and Her 2 neu subtype. The correlation 
was found to be statistically significant (p=0.05). (Table 33 & Chart 27) 
The study population was followed up till October 2010 for a 
maximum period of 17 months. Follow up data was available only for 34 out 
of 60 cases. 25 patients received chemotherapy while 6 of them defaulted 
before completion of the course. 7 patients received hormonal therapy and 10 
patients received radiotherapy. 3 of the Her 2 type tumors presented with 
metastatic deposits in lung, chest wall and ribs while 2 of the luminal A 
subtype patients presented with lytic lesion in the skull bone and with 
recurrent cancer in opposite breast. 
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DISCUSSION 
Breast cancer is the most frequent malignancy in both developed and 
developing countries at the present era. It accounts for 23% of all 
malignancies of women. India bears 8.3% of world burden of newly 
diagnosed breast cancer population with the incidence rate of 22 per lakh 
population1.  
In the present study, immunohistochemical evaluation and gene 
expression analysis were done in 60 invasive ductal carcinoma cases and an 
attempt has been made to correlate the Her 2 neu and Bmi 1 gene expression 
with the known prognostic factors of breast cancers.  
Madras Medical College being a tertiary referral centre, the relative 
frequency of breast cancers among the other surgical cases was 2.1%. Among 
the entire breast specimen received for histopathological examination, 36.22% 
of the cases were reported to be malignant. 
The age of breast cancer patients ranged from 25 years to 75 years with 
the mean age of 48.75 years. The highest incidence of breast cancer occurred 
in 40 to 50 year age group. This is in concurrence with the study done by 
Tanuja et al.69 
The most common histological subtype of breast cancer in this study is 
Invasive ductal carcinoma NOS type. This is almost similar to the study of 
Dixon et al70 and Elston CW Ellis et al71. The incidence of invasive ductal 
carcinoma NOS type is higher in Indian population than that of western 
population (86.13%) accounting for the worse prognosis (Table 34). 
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TABLE 34 - COMPARISON OF DISTRIBUTION OF 
HISTOLOGICAL SUBTYPES OF BREAST CANCERS 
Histological subtypes 
Dixon JM
et al70 
Omar 
Hameed et al24 
Elston CW 
Ellis et al71 
Current 
study 
Invasive ductal 
carcinoma NOS 79% >70% 40 to 75% 86.13% 
Lobular carcinoma 10% 5 to 15% 5 to 15 % 1.26% 
Mixed carcinoma -  10 to 49% 1.68% 
Mucinous carcinoma 2% 1 to 5% 2% 4.2% 
Micropapillary 
carcinoma - 2% <2% 0.84% 
Papillary carcinoma 1% 2% 1 to 2% 2.52% 
Metaplastic carcinoma <1% rare <1% 1.26% 
Tubular carcinoma 6% 1 to 8% 2% - 
Cribriform carcinoma  1 to 3% 0.8 to 3.5% 0.84% 
Medullary carcinoma 2% 1 to 7 % 1 to 7% 0.42% 
Apocrine carcinoma - 0.5 to 4% 0.4% 0.42% 
Adenoid cystic 
carcinoma - rare <0.1% 0.42% 
 
In the study done by Dana Carmen et al72, the incidence of breast 
cancer in premenopausal and postmenopausal women was 38.15% and 
61.85% respectively.72 In concurrence with the above mentioned study, the 
incidence of breast cancer in postmenopausal group was higher (61.67%) than 
that of premenopausal group (38.33%) in the present study. 1% of the total 
breast cancers were reported in males. 49 % of the breast cancers were found 
in left breast, 51% in right breast and 1 case was found to have bilateral breast 
cancer with apocrine carcinoma in right breast and invasive ductal carcinoma 
NOS in the left breast. 
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TABLE 35- COMPARISON OF DISTRIBUTION OF AJCC STAGING 
IN BREAST CANCERS 
Stage 
Madhuri et 
al 
Katrina et 
al 
Carey 
et al 
Al moundhri 
et al 
Current 
study 
Stage I 36.3 46.9 39 6.94 6.66 
Stage II 47.5 42.8 51 43.05 35 
Stage III 11.3 10.4 8 47.22 55 
Stage IV 4.9 NA 3 NA 3.33 
 
Most of the cases presented in stage III followed by stage II which was 
similar to that of Al moundhri et al73 who studied 72 breast cancers in Omani 
population and reported the increased incidence of higher stage tumors in 
their population when compared to the western studies done by Madhuri et 
al43, Katrina et al38 and Carey et al10 in US women.(Table 35) 
A higher proportion of T2 sized tumors (52 %) followed by T3 and T1 
size tumors was seen (Table 36) similar to the study of Lobna Ayadhi et al74 
(Pakistan), Kakil Rassul et al75 (Quatar) and Lakmini et al76 (India).  
TABLE 36 COMPARISON OF SIZE OF TUMORS 
Size 
Lobna Ayadhi et 
al 
Kakil rassul et 
al 
Lakmini et 
al 
Current 
study 
T1 12.9 20 14.5 23 
T2 63.2 47.14 74 52 
T3 23.9 32.86 11.5 25 
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The Grade II tumors were more frequent than other grades of breast 
cancers. This observation was similar to the study carried out by Katrina et 
al38, Carey et al10 and Madhuri et al43 (Table 37).  
TABLE 37 COMPARISON OF GRADE OF TUMOR 
Grade Katrina et al Carey et al Madhuri et al Current study
Grade I 21.9% 25% 13.5% 29.12% 
Grade II 42% 26% 40.8% 52.92% 
Grade III 36.2% 49% 45.7% 17.96% 
 
Nodal metastasis was noted in 48 % of the cases while it was not seen 
in 52%. This result correlates with the study done by Katrina et al38 and 
Madhuri et al43 who reported nodal metastasis in 36.7% and 40.5% of their 
cases. 
58% of cases had lymphatic invasion which was similar to the 
observation made by Fiona blows et al11, who reported 59.1% lymphatic 
invasion in his study.  
Gloria Perio et al77 conducted a study in 238 Spanish breast cancer 
patients and reported vascular invasion in 31.4 % and necrosis in 38.1% of his 
study population. In comparison with the above mentioned study, this study 
also showed the vascular invasion in 22% and necrosis in 52% of the cases. 
There were lymphocytic infiltration in 65% and skin infiltration in 
17% of invasive ductal carcinoma cases, in concurrence to the 33% skin 
infiltration reported in the study conducted by Chanda Bewtra et al78. 
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TABLE 38 COMPARISON OF HORMONE RECEPTORS AND HER 2 
EXPRESSION IN WORLD STATISTICS 
 
ER positive 
(%) 
PR positive 
(%) 
Her2neu positive 
(%) 
Madhuri et al43 71.9 62.2 NA 
Katrina et al38 77.9 66.8 21.7 
D yassin et al81 53.1 44.9 79.6 
Carey et al10 60 56 22 
Kakil rassul et al75 51.42 44.28 26 
Ratnatunga et al80 53.2 50 20.32 
Lobna Ayadhi et al74 59.4 52.3 18.1 
Taucher et al84 77.2 52.7 17.2 
Rodriguez et al85 95.4 78.5 9.2 
Glorio Perio et al77 73.6 67.1 27.8 
Sughayer et al86 50.8 57.5 17.5 
Lakmini et al76 45.7 48.3 19.1 
Tanuja shet et al69 50.5 42 NA 
Vikash kumar et al79 NA NA 46.3 
Current study 41 51 30 
 
The expression of estrogen receptor, progesterone receptor and Her 2 
neu was observed in 41%, 51% and 30% respectively. This proportion was 
similar to the studies conducted by Lakmini et al76, Tanuja et al69 and Vikash 
kumar et al79 in Indian population, by Ratnatunga et al80 in Srilankan 
population and by Kakil rassul et al75 in Quatari population. (Table 38) 
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Her 2 neu over expression and hormone receptor negativity is more 
frequent in Indian population than the western population study data. 
Luminal A is the most frequent subtype observed in this study in 
comparison to the other studies mentioned in the table 39. However, Her 2 
subtype is more frequent and Basal type is less frequent in the Indian 
population when compared to the western population based studies.  
TABLE 39 - COMPARISON OF MOLECULAR SUTYPES 
 Luminal A % 
Luminal 
B % 
Her 2 
% 
Basal 
% 
Unclassified 
% 
D Carmen et al72 53.1 18.5 2.9 21 3.5 
Dalal tamini et al87 25.1 3.4 18.6 10 42.8 
Aitken et al88 56.2 5.23 5.7 18.6 14.3 
Fiona Blows et al11 71 6 6 9 7 
Chin hung lin et al89 61.77 8.75 11.77 12.84 4.86 
Current study 45 12 18 8 17 
 
CORRELATION OF HER 2 NEU EXPRESSION WITH OTHER 
KNOWN CLINICOPATHOLOGICAL PROGNOSTIC FACTORS 
Ake borg et al (1990) studied 280 breast cancer patients in Sweden and found 
direct statistically significant relationship between Her 2 neu expression and 
number of lymph nodes involved, clinical stage, size, absence of hormone 
receptor expression while no association was seen with menopausal status.90 
He reported Her 2 neu as a significant predictor of early relapse and death in 
node positive patients. 
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D Yassin et al (2003) studied the Her family expression in 49 Egyptian 
breast cancer patients and reported statistically significant direct association 
between Her2 expression and positive lymph node metastasis, an inverse 
association with  hormone receptor status and no association with size, grade 
and menopausal status.81 
Susanne Taucher et al (2003) studied Her 2 expression in 923 Austrian 
breast cancer patients and demonstrated significant association of Her 2 
expression in hormone receptor negative status, higher histological grade, 
larger tumor size and younger patients less than 50 years. There was no 
association between Her 2 expression and lymph node status.84 
Mahmoud S Al Ahwal (2006) et al studied 145 Saudi Arabian breast 
cancer patients for Her 2 positivity using Immunohistochemistry and 
correlated with other histopathological features. He reported no correlation of 
Her 2 with age, race, subtype, size, grade, nodal status, lymphovascular 
invasion and progesterone receptor status. He found positive correlation of 
Her 2 neu only with estrogen receptor status.83 
Ratnatunga et al (2007) studied hormone receptor and Her 2 neu 
expression in 124 Srilankan breast cancer patients and reported negative 
correlation of hormone receptors with Her 2 expression. There was no 
significant association found between Her 2 expression and tumor grade or 
age at diagnosis in his study.80 
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Lobna Ayadhi et al (2008) studied the correlation of Her 2 
overexpression with clinicopathological parameters of 155 Tunisian breast 
cancer cases and reported no correlation of Her 2 with age, tumor size, 
histological subtype but it correlated well with tumor grade, lymph node 
metastasis and inversely correlated with hormone receptor expression.74 
Mohammad Naeem et al (2008) studied Her 2 expression in 24 
Pakistani breast cancer cases and demonstrated Her 2 neu positivity to be 
significantly associated with tumor size, negative ER & PR status while no 
association was found with subtype, number of lymph nodes involved and 
grade.82 
In comparison with the above mentioned studies, this present study 
also showed no correlation of Her 2 neu expression with menopausal status, 
tumor size, stage, lymphovascular invasion, lymphocytic infiltration, skin 
infiltration or nodal status. 
There was a direct significant association between Her 2 neu 
overexpression with histological grade of breast cancer which is in parallel to 
the study done by Susanne Taucher et al.84 
There was a significant inverse correlation between Her 2 neu 
overexpression and Hormone receptor status as shown in Table 40. 
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TABLE 40 COMPARISON OF HER 2 NEU CORRELATION WITH 
HORMONE RECEPTOR STATUS 
 
Her 2 neu positivity % in hormone receptor status 
ER + ER- Association PR+ PR- Association
D Yassin et al 73.07 91.3 SS 72.72 88.88 SS 
Mahmud ahwal et al 19.5 80.5 SS 36.6 63.4 NSA 
Mohamad naeem et al 9.09 76.92 SS 16.62 75 SS 
Susanne Taucher et al 9.8 37.1 SS 8 25.4 SS 
Lobna aayadhi et al 7.6 33.3 SS 12.34 24.65 SS 
Ake borg et al 11 32 SS 11 37 SS 
Ratnatunga et al 10.76 31.03 SS 9.8 30.65 SS 
Current study 12 42.85 SS 19.35 41.37 SS 
*SS-statistically significant association; NSA-no significant association 
CORRELATION OF BMI 1 GENE EXPRESSION WITH OTHER 
CLINICOPATHOLOGICAL PROGNOSTIC FACTORS 
Hyun Jo Youn et al (2005) studied the expression of Bmi 1 gene in 71 
Korean patients using both IHC and PCR techniques and demonstrated 62.6% 
expression of the gene in breast cancer. He reported significant increase in the 
expression of Bmi1 mRNA in human breast cancers with strong correlation 
with lymph node metastasis and positive ER status.65  
Javier Silva et al (2006) studied 134 Spanish breast cancer patients and 
reported Bmi 1 expression to be positively correlated with hormone receptor 
status and p53 negativity while no correlation was found with lymph node 
status, size or Ki67. 
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Feng yang et al (2007) studied the expression and significance of Bmi 
1 in Chinese patients by using IHC and reported 82.8% expression in his 
study population. The expression of Bmi 1 positively correlated with higher 
clinical stage, lymph node metastasis while no correlation found with tumor 
size, ER, PR, Her 2 neu expression.91 
Javier Silva et al (2007) studied 111 Spanish breast cancer patients for 
the expression of Bmi 1 gene in plasma by using RT PCR. He reported higher 
expression of Bmi 1 mRNA in cancer patients than healthy controls. The 
higher expression of Bmi 1 correlated with poor prognostic factors such as PR 
negativity and p53 positivity. He suggested to use Bmi 1 gene as a non 
invasive diagnostic marker of poor prognosis.66 
Alexandra M Pieterson et al (2008) studied the expression of EZH2 
and Bmi 1 gene expression in 295 stage 1 and stage 2 breast cancer samples 
in Netherlands. He reported higher expression of Bmi 1 gene with lesser 
grade, ER positivity and luminal A subtype while no association found with 
lymph node status or age at diagnosis.92 
Young Jin Choi et al (2009) studied the expression of Bmi 1 protein in 
960 breast cancer specimen from Korean patients and first reported the 
favourable prognostic association of this gene in breast cancer patients. He 
demonstrated the expression rate of Bmi 1 was significantly higher in patients 
with good prognostic factors such as small tumor size, negative lymph node, 
earlier stage, low nuclear grade and with positive hormone receptor status 
while no significant association was found between Bmi 1 expression and age 
or Her 2 status.67 
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Significant correlation of higher relative expression rate of Bmi 1 
mRNA was observed in the present study with small size tumors and luminal 
A molecular subtype similar to the study done by Young Jin Choi et al67 and 
Alexandra M Pieterson et al92. Correlation was also found with 
premenopausal age group, ER and Her 2 negativity. (Table 41) No correlation 
of Bmi 1 mRNA was found with lymph node status, grade, lymphovascular 
invasion, skin infiltration, lymphocytic infiltration, necrosis or PR status 
which is similar to the observation made by Alexandra M Pieterson et al92. 
TABLE 41 COMPARISON OF RELATIVE BMI 1 GENE 
EXPRESSION 
Tumor characteristics 
AM Pietersen 
et al92 
J Silva et al66 
(2006) 
Current 
study 
Grade 
Grade1 0.0067  2 
Grade 2 -0.15  
 
2.4 
Grade 3 -0.41 4.8 
ER 
Positive -0.08 1.349 1.5 
Negative -0.56 0.715 4.2 
PR 
 
Positive NA 1.447 4.1 
Negative NA 0.68 2.2 
 
Molecular 
subtype 
 
 
 
Luminal A 0.11  3.9 
Luminal B -0.246  0.9 
Her 2 -0.512  2.7 
Basal -0.614  3.4 
Unclassified -0.614  1.3 
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SUMMARY 
60 breast cancer samples were subjected to immunohistochemistry and 
polymerase chain reaction to assess the Her2neu and Bmi 1 gene expression 
and the results were correlated with hormone receptor status and other known 
clinicopathological prognostic factors. 
• The relative frequency of breast carcinoma among other surgical cases 
of Madras Medical College is 2.1%. 
• The non neoplastic breast lesions form 30.24 %, benign tumors 33.54% 
and malignant tumors 36.22%. 
• Breast carcinoma had a peak incidence in the age group of 41 to 50 
years. 
• The most common histological subtype was Invasive ductal carcinoma 
NOS type which constituted 86.13%.  
• 52% of the breast cancer presented with T2 size (2 to 5 cm) tumors. 
• Grade II was the most common grade observed accounting for 52.92%. 
• Nodal metastasis observed in 52 %.  
• Lymphatic invasion and vascular invasion were seen in 58% and 22% 
respectively.  
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• Skin infiltration was seen in 17 % of the tumors. 
• Lymphocytic infiltration was observed in 65% of the tumors. 
• Necrosis was found in 52% of the tumors. 
• Estrogen and progesterone receptor expression was seen in 41% and 
51% of the tumors. 
• Her 2 neu over expression was found in 30 % of the study population. 
• Immunohistochemical molecular subtyping revealed 45% luminal A 
type, 12% luminal B subtype, 18% Her 2 type, 7% basal type and 17% 
unclassified type of tumors. 
• Her 2 neu over expression showed statistically significant association 
with high grade tumors and hormone receptor negativity. 
• No association was found between Her 2 neu expression and 
menopausal status, size, nodal status, lymphovascular invasion, skin 
infiltration, lymphocytic infiltration or necrosis. 
• Higher relative Bmi 1 gene expression was significantly correlated 
with premenopausal age group, small size tumors, ER negativity, Her 2 
neu negativity and luminal A molecular subtype. 
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• No correlation was found between Bmi 1 gene expression and grade, 
lymph node status, PR status, lymphovascular invasion, skin 
infiltration, lymphocytic infiltration and necrosis. 
• Bmi 1 gene expression of this study was not in concordance with the 
results of the studies conducted in Spain 66 and Netherlands 92 while 
higher expression was observed in small size tumors similar to the 
study conducted in Korean population.67 The variation in expression 
could be hypothesized as due to many reasons including racial 
differences between European and Asian population which needs 
extensive and larger study sample . 
• Further studies have to be conducted in future to define the 
clinicopathological importance of Bmi 1 gene expression and the 
possibility of using this gene as an novel prognostic marker in breast 
cancer patients. 
 
 
 
 
 
66 
 
CONCLUSION 
The incidence of Invasive ductal carcinoma NOS was higher in this 
study. Many of our patients presented in younger age with large sized tumors 
accounting for aggressive nature of breast cancer in our population. Her 2 
molecular types were more frequent and Basal type tumors were less frequent 
in the present study when compared to the western literature. Her 2 
overexpression was common with high grade, hormone receptor negative 
tumors. Higher Bmi 1 gene expression was associated with premenopausal, 
small size, ER negative, luminal A subtype tumors in concordance to the 
study conducted in Korean population.67  
Hormone receptor negativity and Her 2 neu overexpression is more 
common in breast cancers of Indian women than the western population. Due 
to high prognostic significance, Her 2 neu should be checked in all breast 
cancer patients so that positive cases can benefit by herceptin therapy and 
anthracycline based chemotherapy which can improve the survival in these 
patients. 
The ethnical difference between European and Asian races may 
explain the variation in the expression of Bmi1 gene expression. However, 
further studies have to be conducted in future on a larger number of samples 
to assess the actual role of Bmi 1 gene expression in Indian population and to 
explore the possibility of using this gene as a novel prognostic marker in 
breast cancers. 
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Figure 1‐ Schematic model of the human breast epithelial hierarchy and potential 
relationships with breast tumor subtypes3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 2: Self‐renewal and differentiation pathways in breast stem cells.  
Loss of BRCA1 &PTEN or activation of the human epidermal growth factor receptor 2, 
Notch,  or  Hedgehog  pathways  result  in  clonal  expansion  of  stem  cells  providing 
targets for further carcinogenic events.2 
 
 
 
 
 
 
FIGURE 3: IMMUNOHISTOCHEMISTRY KIT AND EQUIPMENTS 
 
 
 
FIGURE 4: RNEASY KIT FOR TOTAL RNA EXTRACTION 
 
 
 
FIGURE 5: EPPENDORF BIOPHOTOMETER TO MEASURE 
CONCENTRATION OF RNA 
 
 
 
 
FIGURE 6: PCR TUBES LOADING WITH REACTION MIX 
 
 
 
FIGURE 7: ROTOR GENE Q  WITH ATTACHED SOFTWARE SYSTEM 
 
 
 
 
 
FIGURE 8: AMPLIFICATION PLOT OF FLUORESCENT SIGNALS (15 SAMPLES) 
The amplitude of fluorescent signals increases with amplification. CT value is the cycle at which 
the amplification plot crosses the threshold. Lesser CT value refers to higher Bmi1 mRNA 
concentration in the sample. 
 
 
 
 
DUCTAL CARCINOMA BREAST 
 
Figure 9: Ductal carcinoma – grey white growth with irregular margins 
 
MUCINOUS CARCINOMA 
 
Figure 10: Mucinous carcinoma – glistening gelatinous growth 
PAPILLARY CARCINOMA 
 
Figure 11: Cyst with a papillary growth in the wall presenting as mural nodule 
 
MICROPAPILLARY CARCINOMA 
 
Figure 12: Small grey white growth with adjacent multiple tiny cystic spaces 
MEDULLARY CARCINOMA 
 
Figure13: Grey white fleshy growth with bulging cut surface 
 
METAPLASTIC CARCINOMA 
 
Figure 14: White glistening growth with grey blue cartilaginous areas
 INVASIVE DUCTAL CARCINOMA NOS - GRADE 1 
 
            
    Figure15: Invasive ductal carcinoma NOS    Figure16: Malignant ductal epithelial cells with  
     Tubule formations >90% tumor cells (100X)         mild nuclear pleomorphism & low mitosis  
      HPE 135/09   HPE 135/09 (400X) 
 
 
     
INVASIVE DUCTAL CARCINOMA NOS GRADE 2 
 
            
Figure 17: Sheets of malignant ductal epithelial   Figure 18: Malignant ductal epithelial cells in  
cells, 10%tubule formation                       sheets, tubule 10%, mild nuclear   
HPE 6029/09(100X)                 pleomorphism and mitosis  
                    HPE 6029/09  (400X) 
             
 
INVASIVE DUCTAL CARCINOMA NOS - GRADE 3 
 
   
         
 
 
Figure 19: Malignant ductal epithelial cells in    Figure 20: Malignant ductal epithelial cells 
sheets with focal comedo necrosis    with no tubules, marked nuclear  
HPE 453/09(100X)    pleomorphism, increased mitosis 
              HPE 453/09(400X) 
                 
 
MUCINOUS CARCINOMA  
 
 
           
      
 
Figure 21: Tumor nests floating in mucin lakes    Figure 22: Malignant ductal epithelial cells with 
HPE 1597/10(100X)          mild nuclear pleomorphism and no  
            Mitosis HPE 1597/10 (400X) 
 
 
 
 
LOBULAR CARCINOMA 
 
 
          
 
Figure 23: Tumor cells arranged in lobular    Figure 24: Tumor cells arranged in singles in  
pattern with pagetoid spread around ductal     Indian file pattern : HPE 291/10 (400X)   
elements : HPE 291/10 (100X)         
    . 
 
MEDULLARY CARCINOMA 
 
 
          
 
 
Figure 25: Tumor cells in sheets with lympho    Figure 26: Tumor cells in syncytial   
Plasmacytic infiltrate in periphery      pattern & lymphoplasmacytic infiltrate 
HPE 6156/09 (100X)          HPE 6156/09 (400X) 
 
 
     
 
PAPILLARY CARCINOMA 
 
 
          
 
 
Figure 27: Tumor cells in papillary pattern and    Figure 28: Tumor cells in delicate papillary  
Infiltration : HPE 8635/08 (100X)      pattern: HPE 8635/08  (400X) 
 
 
INVASIVE CRIBRIFORM CARCINOMA 
 
 
          
 
 
Figure 29: Tumor cells in cribriform pattern    Figure 30: Malignant cells in cribriform pattern 
HPE 2640/10 (100X)          and infiltration: HPE 2640/10 (400X) 
 
 
 
 
 
 
 
INVASIVE MICROPAPILLARY CARCINOMA 
 
 
                      
 
Figure31: Micropapillary DCIS with adjacent       Figure 32: Clusters of tumor cells lying  
infiltrating neoplasm (100X)          within clear stromal spaces  
HPE 2683/10               HPE 2683/10 (400X) 
 
 
 
ADENOID CYSTIC CARCINOMA 
 
 
 
          
 
Figure 33: Tumor cells in cribriform pattern with  Figure 34: Basaloid tumor cells in cribriform  
eosinophilic material in spaces      pattern with eosinophilic basement membrane 
HPE 8343/08 (100X)            material in the lumen :HPE 8343/08 (400X) 
 
 
 
APOCRINE CARCINOMA 
 
 
 
           
 
 
Figure 35: Apocrine cells in sheets and nests (100X)  Figure 36: Apocrine cells with abundant  
HPE 8385/08  granular eosinophilic cytoplasm (400X) 
         HPE 8385/08 
 
 
 
METAPLASTIC SARCOMATOID CARCINOMA 
 
 
         
 
 
Figure 37: Spindle shaped tumor cells in sheets   Figure 38: spindle shaped tumor cells with  
and fascicles :HPE 1301/09 (100X)    moderate nuclear pleomorphism and  
mitosis:  HPE 1301/09 (400X) 
 
METAPLASTIC CARCINOMA WITH SQUAMOUS DIFFERENTIATION 
 
          
 
 
Figure 39: Tumor cells in sheets with two     Figure 40: Squamous cell nest in between 
         squamous cell nests : HPE 7719/08 (100X)      tumor cells: HPE 7719/08  (400X) 
 
 
 
 
METAPLASTIC CARCINOMA – CHONDROID DIFFERENTIATION 
 
 
 
                    
 
 
Figure 41: Tumor nest with cartilaginous     Figure 42:Tumor cells with chondrocytic  
differentiation : HPE 7865/09 (100X)      differentiation within lacunae (400X) 
                HPE 7865/09 
 
 
 
 
OTHER PROGNOSTIC FACTORS 
 
           
 
Figure 43:Metastatic deposit in node (40X)    Figure44: Lymphatic invasion (400X) 
   HPE 7453/08               HPE 7776/08 
 
 
 
 
 
 
           
 
Figure 45: Vascular invasion (400X)      Figure 46: Lymphocytic infiltration (100X) 
     HPE 1857/09            HPE 5990/09   
 
 
 
 
 
 
 
 
 
 
         
 
Figure 47: Necrosis : HPE 3984/09 (100X)    Figure 48: Skin infiltration: HPE 2720/09 (100X) 
 
  
 
 
 
ER POSITIVE 
 
 
 
           
 
Figure 49: Invasive ductal carcinoma NOS    Figure 50: Invasive ductal carcinoma NOS 
Strong staining in100% tumor cell nuclei  Strong staining in100% tumor cell nuclei 
with ER antibody : HPE 3011/10 (100X)   Quick score 8(5+3) (100X)          HPE 3011/10 
           
 
 
 
 
 
ER NEGATIVE 
 
           
 
Figure 51: Invasive ductal carcinoma NOS    Figure 52: Invasive ductal carcinoma NOS 
No staining with ER antibody  no staining with estrogen receptor antibody 
Quick score 0 : HPE 5580/09 (100X)  Quick score 0 : HPE 5580/09 (400X) 
 
 
PR POSITIVE 
 
             
Figure53: Invasive ductal carcinoma NOS    Figure 54: Invasive ductal carcinoma NOS 
Strong staining in100% tumor cells           Strong staining in100% tumor cell nuclei  
With PR antibody :HPE 4333/09(100X)           Quick score 8(5+3) (100X) HPE 4333/09 
 
 
 
 
PR NEGATIVE 
 
           
 
Figure 55: Invasive ductal carcinoma NOS    Figure 56: Invasive ductal carcinoma NOS 
No staining with PR antibody: HPE 3799/09(100X)  no staining with progesterone receptor 
antibody; Quick score 0: HPE 3799/09 (400X) 
    
 
 
 
  HER 2 NEU NEGATIVE   HER 2 NEU SCORE 1 
 
 
          
 
Figure 57: No staining in tumour cells with      Figure 58: Incomplete membrane staining 
       Her 2 neu antibody; Her 2 neu score 0      in tumor cells: Her 2 neu score 1+  
        HPE 5200/08 (400X)      HPE 4194/09 (400X) 
 
 
 
HER 2 NEU SCORE 2 
 
 
             
 
Figure 59: Complete membrane staining in    Figure 60: Complete intense membranous 
Less than 30% tumor cells (100X)      staining in less than 30% of tumor cells 
HPE 6576/09             Her 2 neu score 2+: HPE 6576/09 (400X) 
 
 
 
 
HER 2 NEU SCORE 3           
 
 
 
                
 
Figure 61: Complete intense membranous     Figure 62: Complete intense membranous 
Staining in all the tumor cells: HPE 453/09 (40X)    staining in all the tumor cells  
                HPE 453/09 (400X) 
 
 
CYTOKERATIN 5/6 POSITIVE 
 
 
                 
 
Figure 63: Cytoplasmic positive staining with    Figure 64: Cytoplasmic positivity with 
Anti Cytokeratin antibody : HPE 6576/08(100X)   cytokeratin 5/6 antibody in all tumor cells 
              HPE 6576/08 (400X)      
         
 
 
 
CYTOKERATIN 5/6 NEGATIVE 
 
 
        
 
Figure 65: No staining in tumor cells while    Figure 66: No staining in tumor cells with  
internal control(skin) –positive        cytokeratin 5/6 antibody (400X) 
HPE 3929/09 (100X)          HPE 3929/09 
 
 
 
